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1.1  Autosomal recessive cerebellar ataxias: the current  
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Abstract 
Among the hereditary ataxias, autosomal recessive cerebellar ataxias (ARCAs) 
encompass a diverse group of rare neurodegenerative disorders in which a 
cerebellar syndrome is the key clinical feature. The clinical overlap between the 
different cerebellar ataxias, the occasional atypical phenotypes, and the genetic 
heterogeneity often complicate the clinical management of such patients.
Despite the steady increase in newly discovered ARCA genes, many patients with 
a putative ARCA cannot be genotyped yet, proving that more genes must be 
involved. 
This review presents an updated overview of the various ARCAs. The clinical and 
genetic characteristics of those forms with a known molecular genetic defect are 
discussed, along with the emerging insights in the underlying pathophysiological 
mechanisms.
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Introduction 
Ataxia due to involvement of the cerebellum, brainstem and/or spinocerebellar 
long tracts is the key feature of the spinocerebellar degeneration. Clinically, patients 
are characterized by gait impairment, poor balance with frequent falls, disturbed 
upper limb coordination, dysarthria, and eye movement abnormalities. Acquired and 
hereditary forms of degenerative spinocerebellar ataxias are distinguished. 
Based on the mode of inheritance or on the identified genetic defect, hereditary 
ataxias can be further divided into autosomal dominant, autosomal recessive, 
X-linked, and maternally inherited (mitochondrial) disorders. 
 The review provides an updated clinical, genetic and pathophysiological 
overview of the currently known autosomal recessive cerebellar ataxias (ARCAs) 
(Tables 1 -3). In the past few years, several novel forms of ARCA have been 
recognized, based on identified novel loci and genes. Some of these are, however, 
very rare, restricted to isolated populations, or have been described in single 
families only (Table 2). For some of the ARCAs only a locus is known (Table 3). We 
will focus on those ARCAs in which progressive cerebellar ataxia is a prominent 
feature, which are not restricted to single families, and for which the molecular 
genetic defect  is known. The classic and previously extensively reviewed ARCAs 
will be discussed only briefly. The various recessive metabolic diseases in which 
cerebellar ataxia is a clear associated feature are listed in table 4 and will not be 
described in detail. 
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Table 1 Autosomal recessive cerebellar ataxias
Disorder /  
OMIM No.
Locus Gene Protein Gene mutations
Friedreich ataxia 
(FA) / MIM 229300
9q13 FXN Frataxin Intronic GAA repeat  
expansion and  
compound heterozygous 
point mutation
AVED /  
MIM 277460
8q12.3 TTPA a-tocopherol  
transfer protein
Truncating and missense 
mutations
ARSACS /  
MIM 270550
13q12 SACS Sacsin Truncating, missense,  
insertions, small and 
gross deletions
AT / MIM 208900 11q22.3 ATM Serine protein 
kinase
Truncating and missense 
mutations
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Table 1 Continued
Disorder /  
OMIM No.
Locus Gene Protein Gene mutations
ATLD /  
MIM 604391
11q21 MRE11 Meiotic  
recombination 11
Truncating and missense 
mutations
AOA1 /  
MIM 208920
9p13 APTX Aprataxin Truncating, missense,  
insertions, small and 
gross deletions
AOA2/ MIM 
606002
9q34 SETX Senataxin Truncating, missense,  
insertions, small and 
gross deletions
SANDO or MIRAS / 
MIM 607459
15q25 POLG1 DNA polymerase 
subunit  γ-1
Missense and deletions 
A467T en W478S  
associated with MIRAS
MSS/ MIM 248800 5q31 SIL1 Nucleotide  
exchange factor 
SIL1
Truncating, missense, 
insertions and small 
deletions
ARCA1 / MIM 
610743
6q25 SYNE1 Nesprin-1 Missense, splicing and 
small deletions
ARCA2 / MIM 
612016
1q42.2 CABC1 Chaperone activity 
of bc1 complex-like
Truncating, missense,  
insertions, small and 
gross deletions
ARCA3 / MIM 
613627
3p22.1 ANO10 Anoctamin-10 Truncating and missense 
mutations
Table 2 ARCA’s so far only described in one family or in isolated populations 
Disorder /  
OMIM No.
Locus Gene Protein Gene mutations
Infantile onset 
spinocerebellar  
ataxia (IOSCA) /  
MIM 271245
10q24 C10orf2 Twinkle Missense  
(p.Y508C)
Spinocerebellar  
ataxia with axonal 
neuropathy (SCAN1) / 
MIM 607250
14q32.11 TDP1 Tyrosyl-phospho-
diesterase-1
Missense 
(p.H493R)
Autosomal  
recessive spastic 
ataxia-4 (SPAX4) /  
MIM 613672
10p11.23 MTPAP Poly(A) polymerase- 
associated domain- 
containing protein 1
Missense 
(p.N478D)
Salih ataxia /  
MIM 613516
3q29 KIAA0226 Rundataxin Frameshift mutation
13
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Clinical Prologue 
The clinical and genetic heterogeneity among the hereditary ataxias complicates 
their clinical recognition and their diagnostic work-up. In ARCAs (Tables 1-3) 
progressive cerebellar ataxia is usually, yet not invariably, the salient feature. 
However often other neurological or non-neurological symptoms co-exist. The 
overall estimated prevalence is approximately 2.2 -7 per 100,000 but varies per 
population [7]. 
As the different phenotypes are often not so well-defined and may show 
overlapping features, it can be difficult to make a correct clinical diagnosis or 
request the appropriate mutation analysis. For instance, Friedriech ataxia (FA) 
usually presents as an early-onset cerebellar ataxia with neuropathy, while a 
(very) late-onset FA can be associated with marked spasticity of the lower limbs. 
This may resemble autosomal recessive spastic cerebellar ataxia of Charlevoix-
Saguenay (ARSACS) or spastic paraplegia type 7 (SPG7), the latter being a type 
of hereditary spastic paraplegia (HSP) that can also feature a prominent cerebellar 
ataxia [8]. 
 Different classifications of the recessive cerebellar ataxias based on either 
clinical phenotype, neuropathology, or pathogenesis have been proposed. 
However from a clinician’s initial point of view, we suggest to look at the prominent 
features of the different ARCAs and then determine which ARCA to consider first. 
Table 5 gives an overview of the different prominent features that can be 
distinguished among the ARCAs discussed in this review. This table can be used as 
a general guideline, and allows rational selection of an initial genetic screen. 
Given the phenotypic heterogeneity alluded to earlier, a more detailed evaluation of 
the phenotype, including paraclinical studies like laboratory tests and neuro - 
imaging (in particular the presence of cerebellar atrophy is a helpful distinguishing 
feature Figure 1), will be helpful for further differentiation. 
Friedreich’s ataxia (FA)
This is the most common and best characterized recessive form of cerebellar 
ataxia. Typical FA presents as a progressive gait and limb ataxia with onset before or 
around puberty, dysarthria, sensory neuropathy, deep sensory impairment, and 
signs of pyramidal tract involvement. An excellent overview of the clinical picture 
of FA was given by Pandolfo [9] . 
1
GENERAL INTRODUCTION, AIMS AND OUTLINE OF THE THESIS
16
CHAPTER 1
Table 5  Which autosomal recessive cerebellar ataxias to consider based on 
prominent features  
Prominent clinical feature First consider: 
Peripheral neuropathy FA, AVED, SANDO, AT, AOA1, AOA2
Spasticity ARSACS, vLOFA
Oculomotor apraxia AT, ATLD, AOA1, AOA2 
Oculocutaneous telangiectasias AT
Retinitis pigmentosa AVED
Chorea AT, AOA1, AOA2
Dystonia AT, AOA2 
Seizures ARCA2, IOSCA
Myopathy MSS
Cataract MSS
Mental retardation AOA1 , ARCA2, MSS
vLOFA = very late onset Friedreich’s ataxia
Figure 1  Tranversal, T2-weighted MR image showing midline cerebellar atrophy
17
 The estimated prevalence in the Western world  is about 1 in 29,000 with an 
estimated carrier frequency of 1:85 [10]. 
 FA is the result of a homozygous intronic expansion of a GAA trinucleotide 
repeat located in the first intron of  FXN, located on chromosome 9q13 [11]. 
Normal alleles usually carry 6 to 9 GAA repeats. Repeats at the upper end of 
normal (14-34 repeats) can expand during transmission into an intermediate 
range of allele length (up to 90 repeats) or into clearly disease causing alleles 
containing GAA expansions of 90 to 1700 repeats [12]. In a minority (2-5%) of 
cases, the disease is caused by a heterozygous point mutation on one allele 
combined with a GAA expansion on the other allel [13]. The mutations, including 
splice site mutations and deletions, occur throughout the whole gene. 
 FA is caused by partial deficiency of the mitochondrial protein frataxin, which 
is encoded by FXN. The function of the protein is still disputed, but it 
is known to be involved in cellular iron homeostasis. Frataxin binds ferrous 
iron, promoting the mitochondrial synthesis of iron-containing molecules, in 
particular iron-sulfur clusters (ISCs) [14] and haem [15]. It controls the ability of 
iron to perform redox chemistry [16]. Frataxin deficiency leads to a dysfunction of 
the respiratory chain complexes and Krebs cycle components, due to  inappropriate 
ISC synthesis, thus provoking bioenergetics failure and subsequent cell death [17]. 
Complete absence of frataxin is incompatible with life in higher organisms, as 
demonstrated by embryonic lethality seen in systemic gene knock-out models 
[18].
 Potential disease modifying therapeutic strategies aim at reducing the load of 
free radicals in order to slow disease progression. Trials with idebenone have 
shown a reduction in cardiac hypertrophy [19], but no neurological benefit from 
this treatment has been observed. However, based on results of the NICOSIA 
trial,  in which higher doses of idebenone suggested some effect on neurological 
function [20],  idebenone is now being used for symptomatic treatment of FA 
patients in Canada. In Europe and the USA, further trials with  idebenone so far 
have not confirmed the results of the NICOSIA study [21]. Another potential 
therapeutic strategy is aimed at increasing frataxin expression by treatment with 
recombinant human erythrypoietin [22] or histone deacytelase inhibitors [23]. It 
has also been shown that peroxisome proliferator-activated receptor gamma 
(PPARγ) Co-activator 1-alpha, a transcriptional master regulator of mitochondrial 
biogenesis and antioxidant responses, is down- regulated in most cell types from 
FA patients and animal models. 
1
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 This down-regulation may play a role in the blunted antioxidant response 
observed in cells from FA patients  This response can be restored by PPARγ 
agonists, suggesting yet another  potential therapeutic approach to FA [24].
Hereditary Ataxia With Vitamin E Deficiency (AVED)
This disorder resembles FA clinically, but the biochemical hallmark of AVED is a 
very low plasma level of vitamin E (usually < 3µmol /l, normal 7-33 µmol/l) in the 
absence of intestinal fat malabsorption and/or abetalipoproteinemia. The disease 
starts mostly before 20 years, with progressive  cerebellar ataxia, dysarthria, 
reduced or absent deep tendon reflexes, and vibration sense impairment [25]. 
Decreased visual acuity or retinitis pigmentosa may be an early finding. 
Cardiomyopathy is less frequent in AVED compared to FA. Patients seem to have 
more head titubation, less often neuropathy and a slower disease course 
compared to FA [26]. Mild cerebellar atrophy is present in almost 50% of cases 
[27].  The phenotypic variability of AVED can range from a severe FA-like 
phenotype [28] to mild neurological impairment [29], very late disease onset [30], 
or myoclonic dystonia as the initial presentation [31]. 
 The gene involved is called alpha-tocopherol transfer protein (TTPA) [32]. 
Genotype-phenotype correlation studies suggest that truncating TTPA mutations 
correlate with a more severe phenotype than missense mutations [27]. 
 The a-tocopherol transfer protein (a-TTP) mediates the incorporation of 
vitamin E into circulating lipoproteins, and mutations presumably lead to reduced 
vitamin E (A-tocopherol) concentrations. Studies in mice indicate that a-TTP may 
be critical for the uptake of a-tocopherol in the brain and that next to its anti-oxidant 
function, a-tocopherol can modify mitochondrial reactive oxygen species 
production [33]. Further studies are necessary to unravel the exact pathogenic 
mechanism. 
 Importantly, it is known that (early) supplementation with vitamin E appears to 
stop progression of the disease [26], and even may slightly improve cerebellar 
ataxia [34]. 
 The exact incidence of AVED is not known. Most patients originate from North 
Africa where it may be as frequent as FA [35].
CHAPTER 1
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Autosomal recessive spastic cerebellar ataxia of  
Charlevoix-Saguenay (ARSACS)
ARSACS was first described in the Charlevoix-Saguenay region of North eastern 
Québec in Canada [36]. Clinically, ARSACS is characterized by a triad of cerebellar 
ataxia, peripheral neuropathy, and lower leg pyramidal tract involvement. 
 Disease onset is usually in early childhood, although onset in adulthood has 
been described [37]. Oculomotor abnormalities and dysarthria are often mild. 
Slight dysphagia and urinary dysfunction (predominantly urge incontinence) are fairly 
common. 
 Apart from mild dystonic features observed  in a few patients, extrapyramidal 
features are absent [38]. Increased demarcation of the retinal fibers embedding 
parts of the vessels near the disc has been noted [38]. Cerebellar superior vermis 
atrophy, linear hypointensities in the pons, and atrophy of the cerebellar 
hemispheres and spinal cord can be seen on MRI [39]. 
 After identification of the SACS gene involved in ARSACS [40], increasing 
numbers of patients outside Canada were genetically characterized. By now, over 
70 different mutations - truncating, missense, small and large deletions - have 
been identified. SACS encodes the large protein sacsin, of unknown function. The 
protein contains both a functional DnaJ domain, which is able to stimulate Hsp70 
ATPase activity, as well as Hsp90-like ATPase domains. Furthermore, it harbors an 
N-terminal  ubiquitin-like (UbL) domain. The presence of molecular chaperone 
domains and a UbL domain suggest that sacsin may play a  specific cellular role 
in protein folding or complex assembly  [41]. 
Ataxia telangiectasia (AT)
Classical AT is characterized by a progressive cerebellar ataxia starting around 
2-3 years of age. Most patients are wheelchair bound by the age of 10 years. 
Oculocutaneous telangiectasias (figure 2) which usually manifest before the age 
of six are very characteristic of the disease. Oculomotor apraxia (OMA), which is 
almost always present in these patients, and dysarthria are early features. Deep tendon 
reflexes become diminished or absent in older patients. Chorea and dystonia are 
often present. Besides the characteristic telangiectasia, other non-neurological 
features like immunodeficiency, leading to recurrent infections and endocrine 
disturbances (growth failure and diabetes mellitus) complicate the clinical picture. 
1
GENERAL INTRODUCTION, AIMS AND OUTLINE OF THE THESIS
20
Furthermore in approximately one third of patients cancer, usually of lymphoid 
tissues, occurs [42]. Intelligence is thought to be near normal in patients with AT 
[43]. In a very early stage of the disease, MRI of the brain may be normal, but over 
time severe atrophy of the cerebellum is present. In all patients with AT, serum 
alpha-fetoprotein (AFP) concentrations are elevated. Additional abnormal laboratory 
findings are mildly elevated serum transaminases and IgG subclass deficiency. 
Cytogenetic characteristics of AT are DNA radiosensitivity, particularly observable 
in lymphocytes  [44], and chromosomal aberrations such as t(7;14)  translocations. 
Patients with classical AT generally die in the second or third decade of life due to 
malignancies or respiratory failure. Some AT patients display a milder phenotype, 
designated “variant AT ”. This variant phenotype is characterized by either a 
milder classical phenotype witha late onset [45] or by predominant extrapyramidal 
signs, such as chorea-athethosis or resting tremor. 
 In these variant cases lower motor neuron involvement is often present and 
cerebellar ataxia develops later on in the course of the disease or does not occur 
at all. In some variant cases oculocutaneous telangiectasias and immuno deficiency 
are absent and a normal cerebellum is seen on MRI, even at a an older age [46]. 
 The incidence of AT has been estimated at about 1 per 300.000 live births 
[47]. Including AT variant cases, the estimated incidence in the Netherlands is 
1 per 180.000 [48].
 The gene involved in AT is the ATM (AT-mutated) gene. It encodes a protein 
which is a member of the phosphatidylinosytol-3 kinase family of proteins that 
respond to DNA damage by phosphorylating key substrates involved in DNA 
repair and/or cell cycle control [49]. Insights in genotype-phenotype correlations 
is growing: AT patients with a milder phenotype have at least one ATM missense 
mutation with preservation of at least some ATM protein kinase activity [46].
 The ATM protein kinase is involved in early cellular responses to DNA 
double-strand breaks (DSBs) generated during metabolic processes or by 
DNA-damaging agents, like radiomimetic chemicals or ionising radiation. DNA 
DSBs are primary sensed by the Mre11-Rad50-Nbs1 (MRN) complex. This 
complex then recruits ATM to the break, inducing ATM autophosphorylation, 
which leads to an active monomeric ATM. Once activated by the MRN complex, 
ATM phosphorylates members of the MRN complex and a variety of other proteins 
involved in cell cycle control and DNA repair. If the DNA damage is irreparable, 
the network eliminates affected cells by inducing apoptosis [50]. ATM can also be 
activated through chromatin restructuring [51] and it functions directly in the 
repair of chromosomal DNA DSBs by maintaining DNA ends in repair complexes 
CHAPTER 1
21
generated during lymphocyte antigen receptor gene assembly. The latter 
mechanism provides a possible molecular explanation for the increase in 
lymphoid tumors (with translocations) in patients with AT [52]. Thus, ATM helps to 
maintain the integrity of the genome and to minimise the risk of cancer and neuro-
degeneration.
 The use of (routine)radiologic investigations should be minimised, while radio - 
therapy and some radiomimetic chemotherapeutic agents should be avoided 
because of the increased sensitivity of cells from individuals with AT to ionising 
radiation.
Ataxia telangiectasia like disorder (ATLD)
ATLD is a very rare disorder with some clinical features that resemble those of 
AT but with a milder clinical course. ATLD is characterised by moderate radio-
sensitivity, later onset and slower progression of the disease, with longer survival 
and no tumor development [53]. However, Oba et al. recently described two 
siblings with ATLD who both died of lung adenocarcinoma, but it remains to be 
elucidated whether this is truly associated with ATLD [54]. Patients with ATLD show 
no telangiectasias, have no immunodeficiency and serum AFP concentrations 
are normal [55]. 
 ATLD is caused by mutations in the  meiotic recombination 11 (MRE11) gene 
[56]. To date, three truncating and four missense mutations in 18 patients from 
seven different families have been identified.
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Figure 2  Conjunctival telangiectasias in a patient with ataxia telangiectasia. 
Telangiectasias can also be present on sun exposed skin areas.
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 MRE11 forms the core of the multifunctional MRE11-Rad50-Nbs1 (MRN) 
complex that detects DNA DSBs, activates the ATM checkpoint kinase, and 
initiates homologous recombination repair of DSBs [57]. Furthermore, the MRN 
complex plays a role during replication. It prevents replication fork associated 
damage during both “normal” replication and under conditions of stress, and it 
likely has a scaffold function to maintain the replication fork in a competent 
conformation to resume progression during pauses in replication [58]. MRE11 
interacts with itself and both Rad50 and Nbs1. NBS1 is mutated in Nijmegen 
breakage syndrome, which shares chromosome instability and radiosensitivity 
with AT, but in which cerebellar pathology is absent. By using mouse models for 
ATLD and NBS, Shull et al. demonstrated that DNA damage signaling in the 
nervous system is different between ATLD and NBS and likely explains their 
respective neuropathology [59]. 
Ataxia with Oculomotor Apraxia type 1 (AOA1)
AOA1 has some neurological similarity to AT, but in contrast to AT, AOA1 patients 
are not immune deficient and do not display elevated serum AFP concentrations 
[60]. AOA1 is characterized by early-onset progressive cerebellar ataxia with 
cerebellar atrophy on MRI, chorea and severe axonal sensorimotor neuropathy. 
OMA here designated as eye-head dissociation during voluntary lateral head 
movements -the hallmark of the disease- occurs in approximately 80% of cases. 
At onset cerebellar ataxia and chorea are usually the most prominent features, 
whereas oculomotor apraxia and neuropathy are usually absent. Later, severe 
neuropathy dominates the phenotype. After a disease duration of 10-15 years, 
hypoalbuminemia and hypercholesterolemia are seen in most (83%) patients. 
The mean disease duration before patients become wheelchair bound is 11 years 
(range 5-20). Different degrees of cognitive impairment have been described that 
range from severe mental retardation, cognitive deficits characteristic of a 
subcortical syndrome, to normal cognitive function. In France, AOA1 had a 
frequency of 9.1% among individuals with an early onset progressive cerebellar 
ataxia in whom FA has been excluded [61].
 AOA1 is caused by mutations in APTX that encodes the aprataxin protein of 
which two isoforms exists [62]. The longest isoform of  aprataxin contains 3 
functional domains: an N-terminal forkhead-associated (FHA) domain, and a 
central histidine triad (HIT) domain and a C-terminal zinc finger domain. The FHA 
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domain mediates complex formation with XRCC1-DNA ligase IIIa, suggesting a 
role for APTX in DNA single strand break (SSB) repair. The FHA domain of 
aprataxin also interacts with phosphorylated XRCC4 mediating complex formation 
with XRCC4-DNA ligase IV, suggestive of an additional role in double strand 
break (DSB) repair [63].  Most mutations are located in the nucleotide binding HIT 
domain. Cells derived from AOA1 patients are sensitive to DNA SSB-inducing 
agents and show accumulation of single strand breaks under conditions of 
oxidative stress [64] causing specific neuronal cell death. Furthermore a recent 
study has demonstrated that aprataxin localizes to mitochondria and preserves 
mitochondrial function [65]. Aprataxin is expressed ubiquitously, among other 
structures in the caudate nuclei, thus providing a compelling explanation for 
chorea as part of the phenotype [66]. 
Ataxia with Oculomotor Apraxia type 2 (AOA2)
AOA2 is characterised by an onset between 3-30 years and cerebellar ataxia 
associated with axonal sensorimotor neuropathy [67] . OMA is present in only in 
approximately half, or even fewer, of the cases. In a study of 19 patients with 
AOA2 convergent strabismus was more frequent than OMA [68]. Dystonic 
posturing of the hands, choreic movements, and head or postural hand tremor 
can be observed. In contrast to AOA1, the movement disorder in AOA2 usually 
persists and does not disappear over time. Mild cognitive impairment has been 
observed in some patients. [68]. Pronounced cerebellar atrophy on MRI is a 
constant and probably early feature. Increased serum AFP concentration is a 
good biological marker for AOA2. As elevated AFP also occurs in AT, this condition 
should be considered in the differential diagnosis. The study of Anheim et al. 
which has been performed in a part of the French population suggests a 
prevalence of 1/900,000 for AOA2 [69].
 The gene mutated in AOA2, SETX, encodes the nuclear protein senataxin, a 
putative DNA/RNA helicase which shares high homology to the yeast Sen1p 
protein [70]. It  plays a role in DNA repair in response to oxidative stress [71]. 
Mutations include nonsense, missense and frame shift mutations, as well as large 
gene rearrangements. Most missense mutations cluster within the N-terminus 
and helicase domains. Missense mutations located in the N-terminal domain or 
the C-terminal helicase domain cause a less severe AOA2 phenotype and are 
more frequently associated with pyramidal signs and dystonia [72]. 
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Remarkably, heterozygous mutations in SETX may cause a dominantly inherited 
form of juvenile amyotrophic lateral sclerosis (ALS4) [73]. In addition to its role in 
DNA repair, senataxin plays a role in coordinating transcriptional events. Mis -
regulation of transcription and aberrant pre-mRNA processing might contribute 
to the oxidative stress and the neurodegeneration observed in AOA2 [74] .
Sensory ataxic neuropathy, dysarthria and  
ophthalmoparesis (SANDO) or the mitochondrial 
recessive ataxia syndrome (MIRAS)
Two ataxia syndromes (SANDO and MIRAS) have been described that share a 
common underlying molecular pathology. SANDO is characterized by adult- 
onset, severe sensory ataxic neuropathy with dysarthria, ataxic gait and 
progressive external ophthalmoplegia (PEO) [75]. MIRAS refers to a syndrome 
with sensory ataxia, decreased or absent deep tendon reflexes of the lower limbs, 
epilepsy and neuropathy. Cognitive impairment is mild to moderate and 
psychiatric symptoms together with involuntary movements have been described. 
MRI of the brain often displays white-matter changes and thalamic lesions, but in 
some patients only minor cerebellar atrophy or subtle high signal changes 
dorsally from the dentate nucleus occur (Figure 3). The age of onset varies 
between 5-41 years [76]. Both SANDO and MIRAS are caused by mutations in 
POLG1. Two mutations (W748S and A467T) are specifically associated with 
MIRAS.  MIRAS has been reported as the most prevalent cause of recessive 
ataxia in Finland due to a founder effect. 
 POLG1 mutations have been linked to a wide variety of other inherited neuro-
degenerative phenotypes, such as isolated chronic progressive external ophthal-
moplegia, infantile Alpers syndrome, hepatocerebral syndromes  and spinocer-
ebellar ataxia with epilepsy (SCAE) (http://tools.niehs.nih.gov/polg/). Schicks et 
al., identified rather frequent POLG1 mutations (11.3 %) in a cohort of 80 ataxia 
patients. They suggest sequencing of POLG in non-SCA and non-FA ataxia 
patients with PEO, psychiatric comorbidities, and/or axonal neuropathy [77].
 POLG1 encodes the mitochondrial DNA (mtDNA) polymerase-γ and is involved 
in mtDNA replication. The pathogenesis of POLG-related diseases involves 
secondary damage of mtDNA in the form of tissue-specific multiple deletions 
and/or quantitative depletion [78]. This probably leads to energy failure and 
subsequent neuronal cell death [79]. Further studies are needed to clarify the 
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complex pathomechanism of this disorder. Being aware of this molecular defect 
as a potential cause of the syndrome is crucial as the use of sodium valproate for 
epilepsy in patients with POLG1 mutations may trigger liver insufficiency.
Marinesco-Sjogren syndrome (MSS)
The classic features of the rare MSS are cerebellar ataxia with cerebellar atrophy, 
early-onset cataract, psychomotor delay, hypotonia, and progressive muscular 
weakness and atrophy often with elevated creatin kinase levels. Additional findings 
are hypergonadotropic hypogonadism, skeletal abnormalities, short stature, and 
strabismus [80].
 MSS is caused by mutations in the SIL1 gene which encodes a protein that 
interacts with the ATPase domain of GRP78 (HSPA5), a molecular chaperone 
functioning mainly in the endoplasmic reticulum (ER) and required for the proper 
folding of proteins [81].  Not all patients with classical MSS harbor mutations in 
SIL1 suggesting genetic heterogeneity [82]. 
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Figure 3  Symmetric hyperintense signal changes in both cerebellar hemispheres 
just dorsal of the dentate nucleus, on axial T2-weighted image in a 
patient with SANDO.
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Autosomal recessive cerebellar ataxia type 1 (ARCA1)
ARCA1 presents as a pure cerebellar ataxia with a relatively late onset (17-46 
years) and slow progression. The disorder was identified in a French-Canadian 
population, of which 53 individuals from 26 families were affected. Imaging 
revealed diffuse pure cerebellar atrophy [83].
 SYNE1 involved in ARCA1 was the first identified  gene responsible for a 
recessively inherited, pure cerebellar ataxia [83]. Currently, seven different 
truncating disease causing mutations have been identified. These different 
mutations result in a relatively homogeneous clinical phenotype. SYNE1 is one of 
the largest genes in the human genome, comprising 147 exons which encode a 
8797 amino acid long protein, called Spectrin repeat containing Nuclear Envelope 
one. The protein contains two N-terminal actin-binding regions which consists of 
tandem paired calponin homology domains, a transmembrane domain, multiple 
spectrin repeats, and a C-terminal Klarsicht domain. In humans, SYNE1 is 
predominantly expressed in cerebellum. In the peripheral nervous system, SYNE1 
is involved in anchoring specialised myonuclei underneath the neuromuscular 
junctions. The protein is part of the spectrin family of structural proteins that share 
a common function of linking the plasma membrane to the actin cytoskeleton. 
Other  proteins of the family are dystrophin/DMD (Duchenne’s and Becker 
muscular dystrophies), beta-III-spectrin/ SPTBN2 (spinocerebellar ataxia type 5), 
and puratrophin-1/PLEKHG4 (spinocerebellar ataxia type 31). It is speculated that 
the ARCA1 associated loss of function mutations in SYNE1, resulting in loss of 
function of the brain specific larger isoforms, may disrupt cerebellar architecture 
[83]. SYNE1 mutations which do not lead to a complete loss of function are 
associated with other diseases without cerebellar ataxia. Four different missense 
mutations in SYNE1 have been associated with Emery-Dreifuss muscular 
dystrophy [84]. Recently, a splice site mutation leading to lack of the C-terminal 
transmembrane domain KASH, has been identified in a family with autosomal 
recessive arthrogryposis multiplex congenital [85].
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Autosomal recessive cerebellar ataxia type 2 with 
Coenzyme Q10 deficiency (ARCA2)
ARCA2 is a rare ARCA subtype, characterised by childhood-onset gait ataxia and 
cerebellar atrophy with slow progression. Exercise intolerance in childhood and 
slightly elevated serum lactate were present in three out of the seven patients 
described by Lagier-Tourenne et al. All seven patients did not  display coenzyme 
Q10 (CoQ10) deficiency in muscle [86], in contrast to the four patients described 
by Mollet et al. Clinically, these latter patients were characterised by developmental 
delay, elevated serum lactate, seizures and cerebellar atrophy [87].
 ARCA2 is caused by mutations in AARF domain containing kinase 3 (ADCK3), 
also known as chaperone-activity of BC1 complex-like (CABC1), which encodes 
a mitochondrial protein required for coenzyme Q biosynthesis [86]. Recently, the 
first nonsense mutations in CABC1 have been identified in five patients originating 
from two Dutch families [88]. These patients clinically resemble the patients 
described by Mollet et al. So far it has not been proven that treatment with CoQ10 
provides any clinical benefit in patients with ARCA2.
Autosomal Recessive Cerebellar Ataxia type 3 caused by 
mutations in ANO10 (ARCA3)
ARCA3 has recently been described by us as a relatively pure recessive cerebellar 
ataxia, caused by mutations in anoctamin 10 (ANO10). So far, mutations have 
been identified in eight patients from three different families originating from the 
Netherlands, Serbia and France. Clinically ARCA3 is characterized by impaired 
coordination of  limbs and gait with onset between 15-45 years. Brain imaging 
shows cerebellar atrophy. Additionally, lower motor neuron involvement has been 
observed in three patients originating from two different families[89]. 
 ANO10, also known as TMEM16K (transmembrane 16K), is a member of the 
human anoctamin (ANO) family, which comprises at least nine other proteins, all 
exhibiting eight transmembrane domains and a DUF590 domain of unknown 
function [90]. ANO10 may code for a calcium-regulated chloride channel and it 
was suggested that altered calcium signaling in Purkinje cells due to dysfunctional 
or absent ANO10 may play a role in the pathophysiology of ARCA3. Functional 
studies are necessary to confirm this.
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Putative pathogenesis 
Different presumed pathogenesis involved in ARCAs can be distinguished. In this 
review we only discuss the ones involved in the ARCAs described here.
 Six possible disease mechanisms can be distinguished: 1) mitochondrial 
dysfunction; 2) disorder of DNA repair; 3) protein misfolding and chaperone 
dysfunction; 4) mislocalisation of synaptic myonuclei; 5) altered function of 
calcium mediated chloride channels; and 6) altered vesicular trafficking (Box 1).
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Box 1  Classification based on molecular pathogenesis  
Mitochondrial dysfunction
- FA
- AVED
- IOSCA
- SANDO or MIRAS
- ARCA2
DNA repair dysfunction
- AT
- ATLD
- AOA1 
- AOA2
- SCAN1
Protein misfolding and chaperone dysfunction 
- ARSACS
- MSS
Mislocalization of synaptic myonuclei
- ARCA1
Altered function of calcium mediated chloride channel
- ARCA3
Altered vesicular trafficking
- Salih ataxia
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 Increased oxidative stress leading to specific neuronal cell death, caused by 
either mitochondrial dysfunction or operating through DNA repair dysfunction, 
may be a common disease mechanism in ARCAs. Inactivating mutations result in 
the physical absence or the functional loss of the salient proteins. This affects the 
control of energy output, control of DNA maintenance, and cell cycle control. 
 Although different pathogenetic mechanisms are involved in the various 
cerebellar ataxias, it is likely that the products of both dominant and recessive 
cerebellar ataxia genes are all linked in a single or multiple interconnected functional 
network [91], comparable to the Usher interactome [92]. For example, the protein 
encoded by SYNE1 is a member of the spectrin family of which the genes 
PLEKHG4 and SPTBN2, both involved in autosomal dominant spinocerebellar 
ataxia (SCA), are also members. A recent study by Asai et al. demonstrated an 
interaction between the mutated protein kinase C gamma, involved in SCA14, and 
the aprataxin protein involved in AOA1 [93]. As recent studies have shown that 
both mutated aprataxin and TDP1 lead to mitochondrial dysfunction this may turn 
out to be a common pathophysiological mechanism in the different ARCAs [65, 94]. 
Future perspectives
At present, molecular testing is still expensive and in many countries the availability 
of large scale mutation analysis is rather poor. Therefore, focused testing is still 
recommended. In all patients with a suspected ARCA mutation analysis of the FA 
gene should be considered. On the other hand, Salih ataxia, SCAN1, and IOSCA 
(Table 2) are examples of ARCA that so far have only been described in specific 
(isolated) populations, and therefore are not thought of or searched for routinely. 
 Simultaneous testing of ARCA genes by next generation sequencing, 
including exome sequencing, is already available. It is expected that within 1 or 2 
years simultaneous analysis of ARCA genes will be cost effective, and given the 
extensively clinical and genetic heterogeneity and overlap with ARCAs it will be 
the initial molecular genetic test of choice. Also, these new techniques will greatly 
facilitate the identification of novel ARCA genes. New genes will lead to a better 
diagnosis in more patients, which is helpful for determining prognosis and for 
genetic counseling. Eventually, the use of this new technique will make classifica-
tions based on a clinical phenotype, presently still used as a diagnostic guideline, 
redundant. The ultimate ambition is to understand the biology of these devastating 
disorders and to develop targeted treatments. 
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1.2. Aims and outline of the thesis
The autosomal recessive cerebellar ataxias (ARCAs) constitute a heterogeneous 
group of progressive neurodegenerative disorders, characterized by ataxia 
mostly due to progressive degeneration of the cerebellum, spinal cord tracts, and 
connected structures. The clinical phenotype of these disorders is broad and 
quite variable. In contrast to the well-defined clinical-genetic classification of the 
autosomal dominant cerebellar ataxias, less is known about the genetics of 
recessive ataxias. Although several disease genes for recessive ataxias have 
been identified in recent years, among which the frataxin gene for Friedreich 
ataxia and genes for a few other recessive ataxias, the currently identified 
mutations explain only a minority of cases of recessive cerebellar ataxia. A 
substantial number of patients apparently have an as yet unidentified genetic 
disorder. 
 ARCAs have an estimated prevalence in the Netherlands of 5 per 100,000 
individuals. In patients with ARCA, the (spino)cerebellar ataxia often starts at an 
early age, deteriorates over the years, and leads to severe disability later in life. 
Currently, most of these diseases are untreatable. Moreover, a clear diagnosis 
cannot be made in many patients, and therefore counseling on the course of the 
disease is usually not feasible. In addition, genetic counseling of the frequently 
encountered apparently sporadic cases is difficult. 
We aimed to improve our knowledge on the genetic causes of ARCA, to link these 
causes to phenotypic characteristics, and to improve the diagnostic process and 
counseling of patients with these disorders. 
Work described in this thesis covers the phenotypic description of the first 
autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) patients 
identified in the Netherlands; the development and analytical validation of 
conformation sensitive capillary electrophoresis (CSCE) to perform mutation 
scanning of the large SACS gene; and the identification of a novel gene for a 
autosomal recessive cerebellar ataxia. Furthermore, an overview of the different 
ARCAs that can be distinguished so far is presented along with the metabolic 
diseases that can present as an ARCA.
Chapter 1 provides an overview of the phenotypic characteristics and the 
molecular background of different ARCAs known at present.
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Chapter 2 reports two  patients with a congenital disorder of glycosylation type 
Ia (PMM2-CDG), who presented with mainly ataxia and cerebellar hypoplasia and 
with a normal or only slightly abnormal transferrin isofocusing result. Surprisingly, 
the activity of the corresponding enzyme phosphomannomutase was clearly 
deficient in both leucocytes and fibroblasts.
In Chapter 3 the clinical characteristics of the first ARSACS patients identified in 
the Netherlands are described. After detailed neurological, cardiologic and oph-
thalmological examination we could conclude that all patients showed a strikingly 
uniform phenotype. 
Due to the lack of an efficient and cost-effective mutation scanning system 
for the large SACS gene, we developed and validated a simple, rapid, reliable and 
sensitive technique called CSCE for DNA variant identification of SACS (Chapter 4). 
Chapter 5 reports on the identification of a novel gene ANO10,  involved in 
autosomal recessive cerebellar ataxia. For the identification of this gene we 
combined SNP array-based linkage analysis and targeted exome sequencing  in 
the linkage interval in a Dutch consanguineous family with three affected siblings. 
A general discussion on ARCAs and the future perspectives are presented  in 
Chapter 6.
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Abstract 
Cerebellar ataxia can have many genetic causes among which are the congenital 
disorders of glycosylation type I (CDG-I). In this group of disorders, a multi-system 
phenotype is generally observed including the involvement of many organs, the 
endocrine, hematologic and central nervous system. A few cases of CDG-Ia have 
been reported with a milder presentation, namely cerebellar hypoplasia as an 
isolated abnormality. To identify patients with a glycosylation disorder, isofocusing 
of plasma transferrin is routinely performed. Here, we describe two CDG-Ia 
patients, who presented with mainly ataxia and cerebellar hypoplasia and with 
a normal or only slightly abnormal transferrin isofocusing result. Surprisingly, 
the activity of the corresponding enzyme phosphomannomutase was clearly 
deficient in both leucocytes and fibroblasts. Therefore, in patients presenting with 
apparently recessive inherited ataxia caused by cerebellar hypoplasia and an 
unknown genetic aetiology after proper diagnostic work-up, we recommend the 
measurement of phosphomannomutase activity when transferrin isofocusing is 
normal or inconclusive.
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Introduction 
Congenital disorders of glycosylation (CDG) are autosomal recessive metabolic 
disorders characterized by defects in the glycosylation of proteins. CDG type Ia 
(MIM 212065) is the most frequent CDG and is caused by mutations in the phos-
phomannomutase (PMM2) gene located on chromosome 16p13 [1, 2]. Clinically, 
CDG-Ia patients present with a multi-system phenotype that may involve many 
organs. Neurological signs in CDG-Ia can include psychomotor retardation, 
epilepsy, peripheral neuropathy, hypotonia, and ataxia due to cerebellar 
hypoplasia. Just a few cases have been reported with isolated ataxia caused by 
cerebellar hypoplasia without the typical multi-system presentation [3-5]. In these 
cases, an abnormal isofocusing profile of plasma transferrin pointed to the 
diagnosis of CDG-Ia. In this report, we present two similar cases with cerebellar 
ataxia and normal or only slightly abnormal transferrin profiles.
Case reports 
Case 1
A female patient is the second child of healthy consanguineous parents. Both 
siblings are healthy. She was born with a tetralogy of Fallot, for which she had 
surgery. At 5 years of age, she developed coordination problems resulting in a 
disturbed motor development. At 14 years of age, growth delay was noticed with 
a bone age of 11 years. Additional investigation revealed absent ovaries. At that 
time no clinical diagnosis could be made. At the age of 24 years she was referred 
to a neurologist because of increasing coordination problems. A cerebral MRI 
displayed severe hypoplasia of the cerebellum and hemispheres (Figure 1). 
Seven years later she was re-evaluated in our hospital.  At neurological examination 
a young woman of normal intelligence was seen with gaze evoked as well as 
spontaneous nystagmus, mild dysarthria, both mild gait and limb ataxia and 
generalized hypotonia. Routine metabolic screening for CDG showed a slightly 
abnormal transferrin profile (Figure1, lane 1) on subsequent tests. Further CDG 
diagnostics identified deficient PMM enzyme activity in leucocytes (0.09 mU/mg 
protein, reference: 0.41-1.81, CDG-Ia range: 0.0-0.17) and fibroblasts (0.07, 
reference: 1.30-4.58, CDG-Ia range: 0.04-0.59). Mutation analysis of the PMM2 
gene revealed a homozygous missense mutation (c.152A>G;p.Lys51Arg) in exon 2.
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Case 2 
A male patient was born at term as the first child of healthy, non-consanguineous 
parents. His motor retardation became obvious from the age of 5 months onwards. 
On physical examination at 1 year of age he had normal growth parameters and 
slightly abnormal fat distribution in the sub-mamillar region without dysmorphic 
features. Neurological examination revealed minimal spasticity of the lower 
extremities, and both axial and peripheral ataxia. A cranial MRI showed severe 
cerebellar hypoplasia as well as slight cerebral atrophy without other structural 
brain anomalies (Figure 1). Routine metabolic screening at 1 year showed a 
clearly abnormal transferrin profile (Figure 1, lane 2a) and deficient PMM enzyme 
activity in both leucocytes (0.10 mU/mg protein, reference: 0.41-1.81, CDG-Ia 
range: 0.0-0.17) and fibroblasts (0.57, reference: 1.30-4.58, CDG-Ia range: 0.04-0.59). 
CHAPTER 2
Figure 1  Top: Cerebral MRI displaying severe hypoplasia of the cerebellum and 
hemispheres. Left below: Serum transferrin isoelectrofocussing. Lane 1 
shows a slightly abnormal transferrin profile. Lane 2a shows an abnormal 
transferrin profile, lane 2b a borderline abnormal transferrin profile, and 
lane 2c a normal transferrin profile. To= sialotransferrin with no N-glycans, 
T2= sialotransferrin with one N-glycan, T4= sialotransferrin with 2 N-glycans. 
In the table on the right the different percentages of the transferrin isoforms 
are displayed.
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Mutation analysis of the PMM2 gene revealed two compound heterozygous 
missense mutations (p.Arg123Gly/ p.Arg162Trp) [6]. At 7 years, the transferrin 
profile was only borderline abnormal (Figure 1, lane 2b) and had completely 
normalized by 8 years of age (Figure 1, lane 2c). At his present age (10 years), the 
boy has a stable clinical syndrome with ataxic gait and a normal transferrin profile, 
while phosphomannomutase activity in leucocytes remains deficient (0.11, 
reference: 0.41-1.81, CDG-Ia range: 0.0-0.17).
Discussion 
In this report, two patients are presented with cerebellar ataxia. In one patient, 
transferrin isofocusing was only slightly abnormal in the second decade, while in 
the second patient, who initially presented with an abnormal pattern, the 
isofocussing profile had completely normalized in the second decade. The MRI in 
both patients clearly showed cerebellar hypoplasia. So far, two other cases have 
been described with a normal transferrin profile, one as a sibling from a CDG-Ia 
patient with an abnormal profile [7], the other because of a strong clinical 
suspicion of CDG-Ia [8]. Recently, normalization of the transferrin profile in a 
CDG-Ia case was reported in a child with multisystem presentation with prominent 
cerebellar ataxia[9]. So far, no reasonable explanation for these observations has 
been found. The relatively mild clinical presentation in case 1 suggests that the 
homozygous K51R mutation is a mild mutation, which contributes to the geno-
type-phenotype correlation in CDG-Ia. On the other hand, some mutations have 
been associated with a very severe presentation of hydrops fetalis [10]. In general, 
however, no clear genotype-phenotype correlation could be found [11]. In the 
diagnostic protocol of recessively inherited cerebellar ataxia, CDG screening by 
transferrin isofocusing is the standard method. Most patients with enzymatically 
confirmed CDG-Ia clearly show an abnormal transferrin isofocussing profile. 
However, our observations indicate that in rare cases a normal transferrin 
isofocussing profile does not definitely exclude the diagnosis CDG-Ia. Therefore, 
in patients presenting with a recessively inherited ataxia with cerebellar hypoplasia 
and an unknown genetic etiology after proper diagnostic work-up, we advise the 
measurement of phosphomannomutase activity if transferrin isofocusing is normal.
CEREBELLAR ATAXIA AND CDG-IA
2
44
Acknowledgment
We thank M. Hoogeveen for her contribution to patient case 2.
CHAPTER 2
45
Reference List
(1)  Matthijs G, Schollen E, Bjursell C, Erlandson A, Freeze H, Imtiaz F, Kjaergaard S, Martinsson T, 
Schwartz M, Seta N, Vuillaumier-Barrot S, Westphal V, Winchester B. Mutations in PMM2 that 
cause congenital disorders of glycosylation, type Ia (CDG-Ia). Hum Mutat 2000 Nov;16(5):386-94.
(2)  Matthijs G, Schollen E, Pardon E, Veiga-Da-Cunha M, Jaeken J, Cassiman JJ, Van SE. Mutations 
in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient 
glycoprotein type I syndrome (Jaeken syndrome). Nat Genet 1997 May;16(1):88-92.
(3)  Drouin-Garraud V, Belgrand M, Grunewald S, Seta N, Dacher JN, Henocq A, Matthijs G, 
Cormier-Daire V, Frebourg T, Saugier-Veber P. Neurological presentation of a congenital disorder 
of glycosylation CDG-Ia: implications for diagnosis and genetic counseling. Am J Med Genet 2001 
Jun 1;101(1):46-9.
(4)  Mader I, Dobler-Neumann M, Kuker W, Stibler H, Krageloh-Mann I. Congenital disorder of 
glycosylation type Ia: benign clinical course in a new genetic variant. Childs Nerv Syst 2002 
Feb;18(1-2):77-80.
(5)  Bubel S, Peters V, Klein C, Hackler R, Schaefer JR, Hagenah J, Hoffmann GF, Vieregge P. [CDG 
(congenital disorders of glycosylation). Differential hereditary ataxia in adulthood diagnosis]. 
Nervenarzt 2002 Aug;73(8):754-60.
(6)  Matthijs G, Schollen E, Van SE, Cassiman JJ, Jaeken J. Lack of homozygotes for the most frequent 
disease allele in carbohydrate-deficient glycoprotein syndrome type 1A. Am J Hum Genet 1998 
Mar;62(3):542-50.
(7)  Dupre T, Cuer M, Barrot S, Barnier A, Cormier-Daire V, Munnich A, Durand G, Seta N. Congenital 
disorder of glycosylation Ia with deficient phosphomannomutase activity but normal plasma 
glycoprotein pattern. Clin Chem 2001 Jan;47(1):132-4.
(8)  Fletcher JM, Matthijs G, Jaeken J, van Schaftingen E, Nelson PV. Carbohydrate-deficient 
glycoprotein syndrome: beyond the screen. J Inherit Metab Dis 2000 Jun;23(4):396-8.
(9)  Hahn SH, Minnich SJ, O‘brien JF. Stabilization of hypoglycosylation in a patient with congenital 
disorder of glycosylation type Ia. J Inherit Metab Dis 2006;29(1):235-7.
(10)  Vermeer S, van Oostrom CG, Boetes C, Verrips A, Knoers NV. A unique case of PHACES syndrome 
confirming the assumption that PHACES syndrome and the sternal malformation-vascular 
dysplasia association are part of the same spectrum of malformations. Clin Dysmorphol 2005 
Oct;14(4):203-6.
(11)  Erlandson A, Bjursell C, Stibler H, Kristiansson B, Wahlstrom J, Martinsson T. Scandinavian 
CDG-Ia patients: genotype/phenotype correlation and geographic origin of founder mutations. 
Hum Genet 2001 May;108(5):359-67.
CEREBELLAR ATAXIA AND CDG-IA
2

ARSACS in the Dutch population:  
A Frequent Cause of Early Onset Cerebellar Ataxia
Chapter 3
S. Vermeer1
R.P.P. Meijer1
B. J. Pijl2
J. Timmermans3
J.R.M. Cruysberg2
M.M. Bos4
H. J. Schelhaas4
B.P.C. van de Warrenburg4
N.V.A.M. Knoers1
H. Scheffer1
B.P. Kremer4
Radboud University Nijmegen Medical Centre, Departments of Human Genetics1, Ophthalmology2, 
Cardiology3 and Neurology4, Nijmegen, The Netherlands
Neurogenetics (2008) Jul; 9(3): 207-214
48
Abstract
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS: MIM 
270550) is a neurodegenerative disorder characterized by early-onset cerebellar 
ataxia with spasticity and peripheral neuropathy. This disorder, considered to be 
rare, was first described in the late seventies among French Canadians in the 
isolated Charlevoix-Saguenay region of Quebec. Nowadays, it is known that the 
disorder is not only limited to this region but occurs worldwide.
Our objective was to identify cases of autosomal recessive spastic ataxia of 
 Charlevoix-Saguenay (ARSACS) in Dutch patients with recessive early-onset 
cerebellar ataxia by sequencing the complete SACS gene. In a Dutch cohort of 
43 index patients with ataxia onset before  age 25, we identified 16 index patients 
(total 23 patients) with mutations in the SACS gene. Nine of them had homozygous 
mutations and seven of them had compound heterozygous mutations. Retro-
spectively, the phenotype of patients carrying mutations was remarkably uniform: 
cerebellar ataxia with onset before age 13 years, lower limb spasticity and 
sensorimotor axonal neuropathy, and cerebellar (vermis) atrophy on magnetic 
resonance imaging, consistent with the core ARSACS phenotype previously 
described. The high rate of mutations (37%) identified in this cohort of Dutch 
patients suggests that ARSACS is substantially more frequent than previously 
estimated. We predict that the availability of SACS mutation analysis as well as an 
increasing awareness of the characteristic ARSACS phenotype will lead to the 
diagnosis of many additional patients, possibly even at a younger age.
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Introduction
Autosomal recessive spinocerebellar ataxias constitute a heterogeneous group 
of neurodegenerative disorders characterized by ataxia mostly due to progressive 
degeneration of the cerebellum, spinal cord tracts, and associated structures. 
The clinical phenotype of these disorders is broad and quite variable. A number 
of recent reviews presented clinical diagnostic strategies to differentiate between 
the various types of recessive cerebellar ataxias [1-3]. Van de Warrenburg et al. 
grouped them into recognizable and more or less specific phenotypes: (a) ataxia 
with neuro(no)pathy, (b) spastic ataxia, (c) ataxia with oculomotor apraxia and (d) 
Ramsay Hunt syndrome. The most common form, and representative of the first 
group, is Friedreich’s ataxia (FRDA). Autosomal recessive spastic ataxia of Char-
levoix-Saguenay (MIM 270550), ARSACS, is a distinct form of hereditary 
early-onset spastic ataxia. The disease was first described in the Charlevoix-Sa-
guenay region of Northeastern Québec in Canada [4]. Two founder mutations 
were identified in this population [5]. Shortly after mutation analysis became 
available, patients outside Québec were molecularly characterized. To date, apart 
from the two Québec mutations, 27 different additional mutations have been 
found in ARSACS patients outside Quebec, namely from Turkey, Tunisia, Italy, 
Spain, Japan, and recently from Belgium[6-20]. The SACS gene is located on 
chromosome 13q12.12 and encodes the large protein sacsin [5]. Different 
transcripts of the gene have been identified, and in total, 11 different exons within 
the gene have been described. The large transcript NM_014363.4 reported 
recently  (www.ncbi.nlm.nih.gov) comprises nine coding exons consisting of 
13,737 base pairs which encode 4,579 amino acids [6]. The large size of the total 
coding sequence of the SACS gene has precluded sequencing efforts for routine 
diagnostic use. The function of the sacsin protein is not yet known, but the protein 
may be involved in chaperone-mediated protein folding as it contains a DnaJ 
domain and has some sequence similarity with the N terminus of the heat shock 
protein 90 (Hsp90) [5]. As ARSACS is now known to occur worldwide, we initiated 
a systematic mutation analysis by direct automated sequencing of the SACS 
exons and flanking intronic sequences in Dutch patients with an early onset 
cerebellar ataxia, presenting before the age of 25, with the aim of identifying 
additional mutations and determining the relative frequency of ARSACS among 
the autosomal recessive cerebellar ataxias in the Dutch population. 
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Materials and Methods
Patient selection
To determine the frequency of ARSACS among patients with early-onset cerebellar 
ataxia, we included in this study patients who presented with an early-onset 
cerebellar ataxia, before the age of 25 and for whom Friedreich’s ataxia was 
excluded through DNA mutation analysis. According to the clinical information 
which was either given on the DNA mutation analysis request form or gathered 
from medical records, 43 index patients fulfilled this criterion. Patients were 
recruited either through our own neurogenetics out-patient clinic (n=26), as well 
as through referring neurologists and clinical geneticists from other hospitals 
(n=17). Forty-one are native Dutch patients, one patient is of English descent, 
and one is of Turkish descent.  
Molecular analysis
Molecular analysis was performed in 43 index patients. Genomic DNA was 
extracted from blood lymphocytes using standard procedures. We performed 
sequence analysis of the transcript of the SACS gene (NM_014363.4) mentioned 
in the NCBI database (www.ncbi.nlm.nih.gov) that comprises  nine exons. The 
nine coding exons, including the gigantic exon described previously [5], as well 
as flanking intronic sequences of the SACS gene (GenBank reference sequence 
accession number NM_014363.4 (NCBI)) were polymerase chain reaction (PCR)-
amplified from genomic DNA by using 45 primer pairs. The A of the ATG start 
codon in exon 1 is defined as “position 1” for the numbering of nucleotides in 
mutation and DNA-variant nomenclature. Primer sequences and amplification 
parameters are available on request. Purified PCR products (using Multiscreen 
PCRm96 filter plate, Millipore Carrigtwohill,. Cork, Ireland) were directly sequenced 
on an ABI 3730 automated sequencer (Applied Biosystems, Foster City, CA). In 
addition, mutation analysis was performed in affected siblings or relatives of 
patients with one homozygous, or two compound heterozygous mutations in the 
SACS gene. If available, parental DNA was analyzed to confirm the location of the 
mutation(s) in different SACS alleles. In all patients in whom no mutations in the 
nine coding exons of the NM_014363.4 transcript of the SACS gene could be 
identified, we performed molecular analysis of the additional two exons within the 
other transcripts.
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Clinical assessment
A systemic and comprehensive clinical examination by a neurologist, a 
cardiologist, and an ophthalmologist was performed in 16 identified patients, with 
mutations in the SACS gene, of families 1 through 4, 6, 7, 8 through 11, and 13 
(Tables 1 and 2) after having obtained informed written consent. For our clinical 
assessments we used the Scale for the Assessment and Rating of Ataxia (SARA), 
an eight item scale that provides a comprehensive rating of simple ataxia tests: 
(item 1) gait, (item 2) stance, (item 3) sitting, (item 4) speech disturbance, (item 5) 
finger chase, (item 6) nose-finger test, (item 7) fast alternating hand movements, 
and (item 8) heel-shin slide [21]. We generated three composite subscores by 
taking the average scores of the subsets of SARA items. Averaging the scores of 
SARA items 1, 2 and 8 generated a lower body ataxia composite subscore that 
ranges from 0 (no ataxia) to 6 (most severe ataxia). An upper body composite 
subscore consisted of items 5, 6 and 7. The maximum scores on composite 
subscores may range from 0 (no ataxia) to 4 (severe ataxia). 
ARSACS IN THE DUTCH POPULATION
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Table 1 Homozygous or compound heterozygous mutations in SACS gene
Family Consanguinity Mutations Type of mutation 
1 yes p.Gln4054X/ p.Gln4054X Nonsense
2 yes p.Arg728X/ p.Arg728X Nonsense
3 no p.Lys1715X/ p.Arg4331Gln Nonsense/ Missense
4 no p.Gln4054X/ p.Arg2002fs Nonsense/ Frameshift
5^ yes p.Glu1653X/ p.Glu1653X Nonsense
6 no p.Gln4054X/ c.2094-2 A>G Nonsense/ Splice-site
7 yes p.Asp168Tyr/ p.Asp168Tyr Missense
8 no p.Gln4054X/ p.Gln4054X Nonsense
9 yes p.2801delGln/ p.2801delGln In frame deletion
10 not known p.Gln4054X/ p.Gln4054X Nonsense
11 no c.2185+1 del G/ c.2185+1 del G Splice-site
12 not known p.Gln1709X / p.Gln4054X Nonsense
13 no p. Arg321X/ p. Arg3636X Nonsense
14 no p.Gln4054X/ p.Gln4054X Nonsense
15 no p.Arg321X/ p.Trp492X Nonsense/ Nonsense
16^ no p.Leu3304fs/ p.Leu3481Pro Frameshift/ Missense
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Table 2 Phenotypic characteristics of patients with ARSACS
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1 1(M) 3 36 2 +++ 61,1 +++ 25,0 - 30 17 n h a dysphagia,  
urinary dysf.
nd moderate (29)
2 2(F) 3 42 3 +++ 83,3 +++ 37,5 - 20 21,5 n h a +,D severe (35)
3 3(M) 8 45 3 +++ 88,9 +++ 33,3 - 10 21 a n a  urinary dysf. +,D severe  (27)
4 4(F)a 3 33 3 +++ 94,4 +++ 33,3 - 20 23 n n a  urinary dysf. + severe   (24)
5 5(M)b 5 32 2        n a a  nd  
6 6(F) 1 39 3 +++ 86,1 ++ 50,0 - 20 23,5 n h a  urinary dysf. + moderate  (34)
7 7(M) 1 33 3 +++ 86,1 ++ 41,7 - 20 22,5 n h a  nd moderate (24)
 8(F) 3 28 3         h h  nd moderate   (23)
8 9(M) 1 26 2 +++ 66,7 +++ 37,5 + 30 19,5 n h a cystic kidney right, 
dystonic posturing UL
+,D mild      (17)
9 10(F) 2 27 3 +++ 100 +++ 33,3 - 10 23 n n a urinary dysf. + moderate  (18)
 11(F) 1 25 3 +++ 100 +++ 41,7 - 40 27 h h a urinary dysf.,  
dystonia UL
nd nk
 12(M) 1 25 3 +++ 63,9 ++ 41,7 + 30 19,5 n n a dystonia neck + UL, 
dysphagia
+ mild    (12)
10 13(F) 2 29 2 +++ 44,4 ++ 33,3 - 20 14 n h a urinary dysfunction + nk
14(F) 3 31 2 ++ 38,9 + 45,8 - 40 16,5 a a a dysphagia +,D nk
11 15(M) 12 39 3 na 100 +++ 58,3 + 70 28 a a a dysphagia, urinary 
dysf.
nd severe    (30)
 16(M) 6 41 2 ++ 61,1 ++ 37,5 - 10 16,5 a n a impairment, diabetes, 
dysphagia
nd severe   (38)
12 17(F)
18(F)
13 19(M)a 2 56 3 na 100 ++ 54,2 + 70 31,5 a a a dysphagia, urinary 
dysf.
+,D severe  (38)
 20(M) 1 56 3 na 100 na 54,2 na 60 30,5 a a a dysphagia, urinary 
dysf. cognitive  
impairment
+,D severe  (48)
14 21(M) < 10 26 + - steatosis hepatis
15 22 (F) 3 53 3 +  +  -   l n a urinary dysfunction +,D severe (53)
16 23(M)b 9 40 nk + + nk nk b a nk + nk
+ mild, ++ moderate, +++ severe, n normal, h hyperreflexia, a areflexia, – none,  
nk not known, D secondary demyelinating, nd not done, na not able to assess,  
abaclofen pump, bNon-Dutch patients.
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A “remaining” ataxia composite subscore consisted of items 3 and 4 that range 
from 0 (no ataxia) to 5 (worst). Finally, to fully characterize patients and compare 
the three composites we normalized these subscores to percentages of the 
maximum score. Lower body spasticity was separately and semi-quantitatively 
rated according to the INAS (Inventory of Non-Ataxia Symptoms) as, none, mild, 
moderate or severe [21]. Furthermore, the ataxia disease stages were defined as: 
0 = normal; 1 = ataxia, but walking independently; 2 = permanently dependent 
on walking aids; 3 = permanently dependent on wheelchair; and 4 = death [22]. 
If possible, clinical records of previous neurological consultations were reviewed 
to obtain data on the disease progression.
Results
Mutation analysis
In 16 out of 43 index patients, mutations in the SACS gene were identified. In 6 
families the mutations could be confirmed in seven additional affected siblings or 
relatives. We thus identified mutations in 23 patients. Molecular genetic analysis 
revealed nine index patients with homozygous mutations and seven index patients 
with compound heterozygous mutations (Table 1). In total, 16 different novel 
mutations were identified:  eight nonsense, three missense, two splice-site, one 
in frame deletion, and two frame-shift mutations (Table 1). The mutations occurred 
throughout the whole gene, without any hot-spot regions (Figure 1). All mutations 
most likely lead to a loss of function. For the in frame deletion (p.2801delGln) in 
family 9 the prediction programs are inconclusive. Whether this mutation indeed 
leads to a loss of function is unknown. However, the p.2801delGln mutation 
segregated with the disease in the family was not identified in 100 control alleles 
and the mutation is located in a conserved region of the gene. In general, a 3-bp 
deletion is considered to have a larger deleterious effect on the protein function 
than a missense mutation. All three patients carrying the p.2801delGln display a 
relatively severe phenotype, as all were wheelchair-bound before the age of 15. In 
family 3, the identified heterozygous missense mutation (p.Arg4331Gln) is located 
in the highly conserved DnaJ domain in exon 6 of the SACS gene. This mutation 
is predicted to be intolerant (PolyPhen - www.genetics.bwh.harvard.edu/pph/ - 
and SIFT - www.blocks.fhcrc.org/sift/SIFT.html -) and probably leads to loss of 
function of the protein. The mutation (c. 2094-2 A>G) in family 6 presumably 
induces skipping of exon 8 due to loss of the splice-acceptor site (www.fruitfly.
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org/cgi-bin/seq_tools/splice.htlml, www.cbs.dtu.dk/services/NetGene2/, www.
genet.sickkids.on.ca/~ali/splicesitefinder.html ).  Skipping of exon 8 most likely 
leads to absence of sacsin protein. The transcript lacking exon 8 is likely subject 
to nonsense-mediated messenger RNA decay (NMD) due to a downstream 
protein truncating codon (PTC) occurring as a result of a shift of the reading 
frame. The splice site mutation (c.2185+1 del G) in family 11 affects the 
splice-donor site, either leading to a downstream PTC and subsequent NMD, or to 
skipping of exon 8. The identified homozygous missense mutation (p.Asp168Tyr) 
in family 7 is considered to be pathogenic because the amino acid chance is 
predicted to be intolerant (PolyPhen and SIFT), the change is located in a 
conserved region, and was not identified in 100 control alleles. The same mutation 
was also identified in another affected relative of whom both parents were also 
consanguineous within the same extended family. The mutation most likely leads 
to a conformation change of the protein resulting in dysfunction of the protein. 
 The missense mutation identified in family 16 (English descent) is most likely 
pathogenic because it concerns a drastic change of an evolutionary highly 
conserved amino-acid; however, we are still waiting for DNA to confirm the 
mutation in the affected sibling. The nonsense mutation p.Gln3907X,  identified in 
7 out of 14 unrelated Dutch ARSACS patients is a common Dutch nonsense 
mutation. 
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Figure 1  Overview of different mutations in the SACS gene.
M missense, Na founder, N nonsense, Δ deletion, F frameshift, Ss splice-site.
DnaJ 
HEPN 
reverse strand 
NM_014363.4 
M N N Ss Ss N N N N  F  F    N M Na M 
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Clinical data
Twenty-one patients from 14 different families with homozygous or compound 
heterozygous mutations in the SACS gene were of Dutch descent. Family 5 
originated from Turkey and family 16 is from English descent. All patients identified 
were adults, but onset of gait impairment in the 21 patients of whom clinical data 
were available, was before age 13 (mean: 3.7  years, SD 3.1, range: 1-12). The 
mean disease duration in these 21 patients was 36.2 years (SD 9.9, range: 25-56). 
Clinically, all identified patients carrying SACS mutations showed a remarkable 
uniform phenotype: mild to moderate ataxia of the upper half of the body with a 
severe spastic paresis, with sensory and motor neuropathy of the lower limbs and 
very mild motor neuropathy of the upper limbs, and with cerebellar atrophy on 
neuroimaging (table 2). This phenotype is consistent with the core ARSACS 
phenotype previously described.
 At the time of the clinical examination, the majority (n=13) of the patients were 
permanently wheelchair-dependent. The current clinical details in combination 
with older medical records suggest that the initial years of disease were dominated 
by a slowly progressive cerebellar ataxia with subsequent lower limb spasticity, 
followed by features of peripheral neuropathy. This ultimately led to an impressive 
and severe lower limb and gait impairment while oculomotor disturbances, 
dysarthria, and upper limb ataxia appeared to progress much slower. The 
sensorimotor peripheral neuropathy was evident from distal muscle atrophy and 
weakness, foot deformities, impaired tactile and vibration sense and eventually a 
decrease or loss of tendon reflexes in the legs. Slight dysphagia and urinary 
dysfunction (predominantly urge incontinence) were fairly common. Three 
patients ( no.9, no. 11 and no. 12) displayed subtle, yet unequivocal abnormal 
posturing of the hands and/or neck, indicative of mild dystonia in these patients; 
other extrapyramidal features were absent. Two patients (no. 4 and no. 20) used 
an intrathecal Baclofen pump, which influences the outcome of the SARA score 
on lower limb function. In our Dutch ARSACS cohort, no patient was mentally 
retarded nor showed signs of dementia. Only two patients displayed mild 
cognitive problems. One of these (no. 15), had suffered from meningitis at age 44, 
and developed diabetes at age 56. He had experienced a recent episode of 
epileptic seizures. The other patient (no. 20) had suffered from strokes.  In 15 
patients who had undergone a brain MRI or CT-scan, moderate to severe 
mid-cerebellar (vermis) atrophy was noticed, the severity of which appeared to 
parallel disease duration. In 12 patients an electrocardiogram (ECG) was made 
and echocardiography was performed. One patient (no. 1) showed a right bundle 
CHAPTER 3
57
branch block on ECG; no other ECG abnormalities were seen, either in this patient 
or in any other. None of the examined patients displayed signs of mitral valve 
prolapse or any other cardiac abnormalities on echocardiography. On 
ophthalmologic examination, all 14 patients that were examined, showed 
demarcation of the retinal nerve fibers that embedded parts of the vessels near 
the disc (Figure 2). 
In one patient (no.7), a papilla leporina could be seen. In patients no. 19 and no. 
20 no ophthalmologic examination and cardiologic examination was done, and 
no cardiologic examination could be performed in patient no. 6 due to limited 
mobility.
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Figure 2  Red-free fundus photograph of patient no. 12; increased demarcation of 
the retinal nerve fibers, partially embedded retinal vessels and a distinct 
tortuosity of the retinal vessels near the optic disc are seen.
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Discussion
In this report, we demonstrate that in the Dutch population, mutations in the SACS 
gene are quite prevalent among patients with early-onset cerebellar ataxia. 
Moreover, those who harbored mutations in the SACS gene showed a strikingly 
uniform and recognizable clinical phenotype consisting of cerebellar ataxia with 
onset before the age of 13, lower limb spasticity and sensorimotor axonal 
neuropathy, and cerebellar (vermis) atrophy on neuroimaging.
 Originally believed to be a rare disease that was present in Quebec only, 
ARSACS turns out to constitute a fairly common phenotype in the diverse group 
of early onset recessive cerebellar ataxias. We identified many different novel 
mutations throughout the whole gene. The clinical phenotype is specific and 
recognizable, thus offering a good indication for mutation analysis. In this study 
the detection rate of ARSACS mutations in the SACS gene among 43 patients with 
an early onset recessive cerebellar ataxia was 37%.  Retrospectively, we can 
conclude that all identified ARSACS patients displayed mild to moderate upper 
body ataxia and severe spastic paresis of the lower limbs with neuropathy. In two 
patients with more or less similar neurological features no mutations in the SACS 
gene could be identified.  This might be due to genetic heterogeneity for the 
spastic ataxia phenotype. The principle of genetic heterogeneity for the spastic 
ataxia phenotype is demonstrated by reports of patients with spastic ataxia who 
harbor mutations in the FRDA gene and of patients who are linked to the SPG30, 
SAX2 and ARSAL loci [23-28]. 
 Furthermore, in retrospect, these two patients had less lower limb spasticity 
compared to the ARSACS patients and, contrary to these, prominent atrophy and 
weakness of the intrinsic hand muscles. On the other hand, we cannot exclude 
that mutations in both SACS alleles might have remained undetected, for instance 
when they reside in parts of the gene that have not been analyzed, e.g. regulatory 
regions upstream of the gene, or deep in the introns. The average age of onset of 
the disease in our cohort is comparable to what has been described in literature, 
except for one Tunisian case in whom the age of onset was 20 years [29].
 Mitral valve prolapse has been mentioned as a frequent feature among 
ARSACS patients from Quebec [4]. After the publication of Bouchard et al.[4] 
cardiac involvement in ARSACS patients has not been further reported. This is 
consistent with the absence of cardiac symptoms in patients from our cohort. 
Therefore, we conclude that cardiac involvement is not a clinical characteristic of 
ARSACS. 
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Increased demarcation of the retinal fibers embedding parts of the vessels near 
the disc has previously been reported as being a common feature of ARSACS 
among patients originating from Quebec and of some other ARSACS patients [4, 
8, 9, 13, 15, 30, 31]. Eight of the 14 patients whom we ophthalmologically examined 
not only did show increased demarcation of the retinal nerve fibers but also had 
a distinct tortuosity of the retinal vessels near the optic disc (figure 2). 
 Our data demonstrate that mental retardation, defined as having an IQ of less 
than 70, is not a feature of ARSACS. So far, only two ARSACS patients described 
in the literature fulfill this criterion. However since their spastic-ataxic sibs were 
not mentally retarded the retardation is most likely an independent feature not 
related to ARSACS [13, 17]. In three patients, mild dystonic features were 
observed. Dystonia has not been reported in other ARSACS patients, but 
extrapyrimadal features such as dystonia and chorea are known to occur in 
Friedreich’s ataxia, ataxia telangiectasia, ataxia with oculomotor apraxia type 1, 
and ataxia with vitamin E [32-35]. So far, only two adult ARSACS patients (with 
mutations in the SACS gene) without lower limb spasticity have been reported. 
The absence of this feature was suggested to be due to the severe progressive 
neuropathy that could mask spasticity [9, 18]. Assuming a uniform clinical 
ARSACS phenotype, and given the still labor-intensive procedure of fully 
sequencing this large gene, it seems currently advisable to screen the SACS 
gene only in those patients who present with early-onset slowly progressive 
cerebellar ataxia, with lower limb spasticity and peripheral neuropathy, with 
relatively mild oculomotor disturbances and upper limb ataxia, and in whom 
Friedreich’s ataxia has been excluded.  
 In conclusion, 16 novel SACS mutations were identified in 16 different families 
consisting of 23 patients in whom the clinical phenotype was very similar and 
consistent with the core ARSACS phenotype,  mild to moderate upper body 
ataxia and severe spastic paresis of the lower limbs and neuropathy, with 
cerebellar atrophy revealed by neuroimaging. The identification of several different 
mutations in the SACS gene in this first mutational screen in Dutch patients with 
an early onset cerebellar ataxia indicates that ARSACS is more prevalent in the 
Dutch population than previously assumed. This could also be the case in other 
populations. 
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Abstract
In this study, we developed and analytically validated a fully automated, robust 
confirmation sensitive capillary electrophoresis (CSCE) method to perform 
mutation scanning of the large SACS gene. This method facilitates a rapid and 
cost-effective molecular diagnosis of autosomal recessive spastic ataxia of Char-
levoix-Saguenay. Critical issues addressed during the development of the CSCE 
system included the position of a DNA variant relative to the primers and the 
CG-content of the amplicons are discussed. The validation was performed in two 
phases; a retrospective analysis of  32 samples containing 41 different known 
DNA variants and a prospective analysis of  20 samples of patients clinically 
suspected of having autosomal recessive spastic ataxia of Charlevoix-Saguenay. 
These 20 samples appeared to contain 73 DNA variants. In total, in 32 out of the 
45 amplicons, a DNA variant was present, which allowed verification of the 
detection capacity during the validation process. After optimization of the original 
design the overall analytical sensitivity of CSCE for the SACS gene was 100%, 
and the analytical specificity of CSCE was 99.8%. In conclusion, CSCE is a robust 
technique with a high analytical sensitivity and specificity, and it can readily be 
used for mutation scanning of the large SACS gene. Furthermore this technique 
is less time consuming and less expensive, as compared with standard automated 
sequencing. 
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Introduction
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) belongs 
to a heterogeneous group of neurodegenerative disorders characterized by 
ataxia, mostly due to progressive degeneration of the cerebellum and associated 
structures. The clinical phenotype of these disorders is broad and quite variable. 
Clinically it can sometimes be hard to distinguish the different types of cerebellar 
ataxia. Molecular diagnosis can be extremely helpful to differentiate between the 
different forms of ataxia.
 Using DNA analysis to confirm the clinical diagnosis of ARSACS (MIM 270550) 
has been hampered in the majority of  patients worldwide due to the lack of an 
efficient and cost-effective mutation scanning system for the SACS gene. The 
large size of the total coding sequence of this gene has precluded sequencing of 
the total coding sequence of the SACS gene as a routine diagnostic service. 
Since automated sequencing of this large gene is labor- intensive, costly, and 
time consuming, we developed mutation screening by designing a heteroduplex 
analysis system using conformation sensitive capillary electrophoresis (CSCE), 
which is a simple, rapid, reliable and sensitive technique enabling a high sample 
throughput [1] and automated DNA variant identification. We have chosen this 
method because it can be used for the analysis of larger fragment sizes (up to 
500 bp), it has a higher sensitivity and it can easily be implemented in existing 
automated sequencer infrastructure. DNA analysis therefore becomes more 
reliable, more robust, less expensive, and has a higher throughput, in comparison 
with established techniques such as single-strand confirmation polymorphism, 
denaturing gradient gel electrophoresis, and denaturing high performance liquid 
chromatography [2]. 
 The SACS gene involved in ARSACS is located on chromosome 13q12.12 and 
encodes the large protein sacsin [3]. The gene consists of at least 11 exons, of 
which 9 contain coding sequences, spanning 13,737 base pairs and 4579 amino 
acids (NM_014363.4). 
 To date, apart from the two mutations originally identified in the ARSACS patients 
from Québec, 30 different additional mutations, including nonsense, missense, 
small deletions and insertions, have been identified in ARSACS patients from 
different countries. These mutations occur throughout the entire gene. 
 Not all types of mutations will be detected by sequencing or alternative subtle 
mutation scanning techniques such as CSCE. 
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For instance, recently a Belgian ARSACS patient has been described with a 1.5 
Mb deletion on chromosome 13q12.12 encompassing the SACS gene and a 
missense mutation on the other allele [4]. This underlines that additional mutation 
detection techniques will still be needed.
 Here, we report the development of a fully automated, robust CSCE method 
to perform mutation scanning of the large SACS gene, facilitating a rapid and 
cost-effective molecular diagnosis of ARSACS patients. 
 Since the cohort of Dutch ARSACS patients had been thoroughly analyzed 
for SACS mutations by automated direct sequencing, a good starting point for 
the analytical validation of the CSCE mutation scanning including automated 
hetero duplex pattern analysis had already been created.  A technical validation 
of the CSCE technique in general has been performed as an interlaboratory 
collaborative project previously [5]; details will be published elsewhere. The 
analytical validation of CSCE specifically for the SACS gene presented here has 
been performed in two phases; a retrospective analysis of samples containing 
known DNA variants in the SACS gene and a prospective analysis of samples of 
patients for whom SACS mutation analysis was requested by a physician. Issues 
to be addressed during the development of a CSCE system for mutation scanning 
are discussed and illustrated with examples. These include the position of a DNA 
variant relative to the primers, and the CG-content of the amplicons. Finally an 
overview of all novel SACS mutations and single nucleotide polymorphisms 
(SNPs) identified in a cohort of 76 patients for whom SACS mutation analysis was 
requested is presented (Tables 1 and 2). 
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Materials and methods
Patients 
Peripheral blood was collected using EDTA as an anticoagulant from index 
patients with recessive cerebellar ataxia. Automated genomic DNA extraction 
was performed using a Tecan Freedom EVO® 150 workstation combined with a 
Chemagic Magnetic Separation Module 1 from Chemagen. The concentration of 
DNA samples were standardized at 100 ng/µl. For the validation in total 52 DNA 
samples of patients were used who either have ARSACS confirmed at the DNA 
level or known variants in the SACS gene (retrospective phase), or who were 
suspected of having ARSACS (prospective phase). The remaining 24 patients of 
whom mutation data were available have not been included in the validation 
study to avoid redundancy, ie, no additional fragments would have been validated 
by their inclusion. To facilitate the detection of homozygous mutations, before 
CSCE, the PCR product of a patient was mixed with PCR product of a mutation-
negative reference sample to allow the formation of heteroduplex bands. For this 
purpose, we used two different reference samples (V3 and V4). These samples 
were sequenced in advance to identify the DNA variants present in the different 
amplicons of the SACS gene. Informed consent was obtained from all patients 
included in this study.
PCR Amplification
We designed 45 overlapping PCR primer pairs for the nine coding exons (Table 
3), including the gigantic exon 9 described previously [3] and the flanking intronic 
sequences of the SACS gene (GenBank reference sequence accession number 
NM_014363.4, NCBI). All Forward Primers (FPs) and Reverse Primers (RPs) 
contain next to the specific primer an universal primer tag (M13), (FP) 5’-TGTA-
AAACGACGGCCAGT-3’ and (RP) 5’-CAGGAAACAGCTATGACC-3’. The primer 
sequences, positions and size of each amplicon are listed in Table 3. The DNA-
amplification mix included (per amplicon per sample) 1.0 µl genomic DNA, 0.36 
µl (8.33 mmol/L) dNTPs, 1.44 µl MgCl2 (50mM, AB), 1.80 µl 10x PCR Gold Buffer 
(AB), 0.14 TaqDNA polymerase Gold (5 U/µl), 6.26 µl distilled H2O (mQ), and 7 µl 
FP and RP (10 pmol/µl) from a mix of 0.16µl FP and RP per 1µl mQ. The reaction 
volume per sample was 18 µl. The samples were PCR amplified using the following 
PCR program on a Perkin-Elmer (ABI) Geneamp® 9700: an initial denaturation at 
94ºC for 5 minutes, followed by 35 cycles of denaturation at 94ºC for 30 seconds, 
annealing at 58ºC for 30 seconds, and elongation at 72ºC for 1 minute, with a 
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final step at 72ºC for 7 minutes, after which the samples are cooled down to 10ºC. 
Before CSCE, 5 µl of each PCR-product with 7 µl Loading Orange G was run on a 
1% agarose gel with a 100-bp marker for comparison. Next, all PCR-products (13 
µl) were purified using a Multiscreen PCRµ96 filter plate (Milipore, Tullagreen, 
Carrigtwohill, County, Cork, Ireland).
 For fragment 2 (exon 2) a different PCR program and amplification mix is 
used; 0.5 µl  (8.33 mmol/L) dNTP’s, 3.0 µl  MgCl2,  3.0 µl PCR Gold Buffer, 7.5 µl 
Betaine, 0.2 µl Tag DNA polymerase Gold, 13.8 mQ, 1 µl FP and RP (10 pmol/ µl) 
with 1.0 µl genomic DNA in a total reaction volume of 30 µl per sample. The PCR 
program is as follows: initial denaturation at 94ºC for 5 minutes, then 38 cycles of 
denaturation at 98ºC for 5 seconds, annealing at 68ºC  for 30 seconds, and 
elongation at 72ºC  for 50 seconds, with the final step at 72ºC  for 7 minutes, after 
which the samples are cooled down to 10ºC.
CSCE
During CSCE, the target gene is PCR-amplified and PCR products are denatured 
and re-annealed slowly, so that four different double stranded (ds) DNA molecules, 
ie, two homoduplexes and two heteroduplexes, can be formed if a heterozygous 
mutation is present. To identify conformational changes resulting in a mobility 
shift, the re-annealed PCR products can be analyzed using any capillary DNA 
sequencer, and by using non-denaturing conditions, ie, an ABI 3730 sequencer 
with conformation analysis polymer-containing capillaries. The re-annealed PCR 
products can be detected by using a four-dye filter set, and fluorescently-labeled 
primers. The presence of many SNPs in the gene of interest will lead to the 
identification of these as DNA variants in several samples, depending on their 
allele frequency. These DNA variants will all have to be subsequently analyzed by 
automated sequencing. CSCE therefore is most suited for genes containing just 
a limited number of (common) SNPs. The peak patterns are analyzed automatically 
by specially designed software (BioNumerics, Applied Maths, St- Martens-Latem, 
Belgium).
CSCE conditions
Prior to CSCE 5 µl purified PCR-product was mixed with 2 µl PCR-product of a 
mutation-negative reference sample (V3). For the amplicons 7 and 10 of the 
SACS gene a different reference sample (V4) was used since the V3 sample was 
hetero zygous for common SNPs in these amplicons. 
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CSCE-BASED MUTATION SCANNING OF SACS
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The labeling-PCR mix contained 0.2 µl fluorescently carboxyfluorescein-labeled 
FP, 0.2 µl Reverse M13 primer, 0.5 µl dNTPs (8.33 mmol/L), 1.5 µl MgCl2 (50 
mmol/L, AB), 2.5 µl 10´ PCR Gold Buffer (Applied Biosystems, Inc, Foster City, 
CA, USA), 0.2 µl TaqDNA polymerase Gold (5 U/µl) and 17.9 µl mQ. Of this mix 18 
µl was used per sample for the labeling-PCR. The following PCR program was 
used for the labeling-PCR: an initial denaturation at 94ºC for 5 minutes, followed 
by 10 cycles of denaturation at 94ºC for 30 seconds, annealing at 58ºC for 30 
seconds, and elongation for 1 minute at 72ºC, with a final step at 72ºC for 7 
minutes after which the samples are cooled down to 10ºC. After the labeling-PCR, 
the products (25 µl) are again purified as described before. Per sample 1 µl 
pooled PCR product, was mixed with 9 µl standard LIZ-500 (Applied Biosystems) 
/ mQ-mix (in proportion 0.2 µl Liz to 8.8 µl mQ), before running the actual CSCE. 
The analysis was performed using an ABI 3730 automated sequencer (Applied 
Biosystems) using capillaries containing conformation analysis polymer. Results 
were analyzed using BioNumerics 5.0 (Applied Maths NV, Sint-Martens-Latem, 
Belgium) software. We choose to run four patient samples in a single CSCE run. 
Automated CSCE Pattern Analysis
To automatically analyze the CSCE electropherograms of the different amplicons 
of the SACS gene by the data analysis software program Bionumerics an 
optimized set of parameters (quantified characteristics of the shapes of the 
 electropherogram) has been used. 
 The parameters include (1) the relative position of the peak within the electro-
pherogram, and (2) the signal-width as a percentage of the run length, and (3) the 
left and right control range, ie, the area flanking the main peak signal in which the 
algorithm will search for additional peaks. To further characterize the shape of the 
peaks (curves), the algorithm calculates five different pattern-matching parameters, 
ie, SRMS, MAX, SECPK, DFH3, and DFH4. SRMS stands for single- sided root 
mean square value, and is calculated from the highest 50% of square differences 
between the curves compared. MAX determines the highest difference between 
any corresponding values on the two curves. SECPK calculates the proportion of 
a secondary peak relative to the primary peak of the curve. DFH3 is a parameter 
for the difference in H3 parameters between the signal and the reference (H3 is 
a measure of the deviation from symmetry, compared with a Gaussian curve 
derived from reference samples without DNA variants), whereas DFH4 determines 
the deviation from a theoretical Gaussian curve. The parameters SRMS and MAX 
take into account any difference between the curves, the parameters SECPK, 
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DFH3 and DFH4 each apply to a specific component of the curve. For a correct 
match interpretation a peak height has to be above 1000 and below 32000 relative 
fluorescent units. Peak heights outside this range will be regarded as failures by 
the BioNumerics program.
Sequence analysis
In this validation study, all samples have been analyzed in parallel by CSCE and 
by automated sequencing. Sequence reactions were run on an ABI 3730 
automated sequencer and analyzed with a combined software program: Phred, 
Phrap and Polyphred (University of Washington). In affected siblings or relatives 
of patients with one homozygous or two compound heterozygous mutations in 
the SACS gene, the presence of the mutations was identified or excluded using 
direct sequencing. Due to the occurrence of two relatively frequent polymorphisms 
in amplicon 35 which are heterozygous in both reference samples V3 and V4, 
direct sequencing is preferred over CSCE for this amplicon, since aberrant 
heteroduplex patterns will occur in the majority of cases. As the PCR-mix and 
program conditions for exon 2 of the SACS gene differ substantially from standard 
conditions, CSCE conditions for this specific exon have not been developed.
Results
Design
Primers were designed (a) to allow for an identical annealing temperature for all 
45 amplicons, except for amplicon 2 (exon 2) for which a different annealing 
temperature is used because of the high CG-content of this fragment, (b) to 
obtain amplicon sizes ranging from 299 to 585 bp in length, (c) to allow for a 
distance of at least 30 bp between the 5’-end of a particular primer and the 
nearest exon-intron boundary within the amplicon, and (d) to have at least 100 bp 
overlapping sequence for neighboring amplicons of the same exon. An overlap 
will ensure the identification of a heterozygous deletion encompassing a single or 
multiple amplicons that could otherwise escape detection. Furthermore a minimum 
of 30 base pairs between the beginning of a primer and an exon-intron boundary 
are present in each amplicon, where applicable. To enable a rapid confirmation 
by automated sequencing of sequence variants identified by CSCE, the amplicons to 
be analyzed by CSCE were identical to the amplicons to be analyzed by sequencing. 
CSCE-BASED MUTATION SCANNING OF SACS
4
78
This approach also reduces the consumable costs, since identical primer pairs 
for both CSCE as well as sequencing can be used. This method is feasible, since 
there is no need to split amplicons into smaller fragments to comply with the presence 
of multiple melting domains, like in denaturing gradient gel electrophoresis- or 
denaturing high performance liquid chromato graphy-based approaches.
 To automatically analyze the CSCE electropherograms of the different amplicons 
of the SACS gene by the data analysis software program Bionumerics an optimized 
set of parameters (quantified characteristics of the shapes of the electrophero-
gram) has been used that was developed during a separate technical validation 
of CSCE. Essentially, the position and shape of the peak of a normal (no DNA 
variant-containing) reference electropherogram is compared with the peak 
positions and shapes of the electropherogram to be analyzed. The parameters used 
are described in the Materials and Methods. 
Validation
A generic technical validation of the experimental conditions of CSCE and the 
optimal general settings of the software program BioNumerics has already been 
performed previously. In this collaborative study (Inter-laboratory Diagnostic 
Validation of Confirmation Sensitive Capillary Electrophoresis, to be published in 
detail elsewhere) parameters including (1) CG-content of fragments, (2) position 
of the DNA-variant relative to the primers, (3) fragment length and (4) temperature 
during electrophoresis have been analyzed. 
 The main results are that: (1) CG-content of 30-60% gives optimal results, 
whereas for amplicons with a CG-content up to 80% different conditions may be 
necessary, (2) SNPs close to a primer may escape detection, an issue that can be 
circumvented by the design of the analytical strategy, eg, by taking sufficient 
overlap of amplicons into account, (3) length of amplicons up to 500 bp can still 
be analyzed reliably, and (4) cooling of the oven temperature below 15 ºC, which 
improves separation of heteroduplex bands [5].
 As a result of the design and analytical validation of the CSCE system for mutation 
scanning of the SACS gene presented in this paper, the five pattern matching 
parameters were set at specific lower and upper threshold values (Table 4). Patterns 
with parameter values above one or more of these thresholds are considered to be 
divergent (indicated by red) and patterns with one or more parameter values below a 
certain threshold are considered to be normal (indicated by green). Patterns  with one 
or more parameter values between these two thresholds are slightly divergent 
(indicated by orange). These patterns always need to be visually inspected. 
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 For analytical validation of the use of CSCE to the detection of DNA variants 
specifically in the SACS gene in total 52 DNA samples containing a total of 51 
different variants occurring in 32 different amplicons of the SACS gene have been 
analyzed. The PCR products ranged in length between 299 to 585 bp. The 
validation process consisted of a retrospective phase and a prospective phase. 
In the first phase, 32 DNA samples of  index patients with known variants, 
previously identified by sequencing of the SACS gene were used retrospectively 
to determine the analytical sensitivity of the CSCE approach. In the second 
phase, to further assess the analytical sensitivity and to determine the analytical 
specificity, we performed CSCE and subsequent sequencing of the SACS gene 
prospectively in a cohort of 20 DNA samples from patients for whom mutation 
analysis of the SACS gene was requested for clinical purposes.
Phase one (Retrospective analysis):
To test the analytical sensitivity of the CSCE, 32 DNA samples containing 41 
different known variants were retrospectively used. These 41 known variants occur in 
25  different amplicons (4/29 amplicons are redundant due to overlaps with flanking 
amplicons) of the SACS gene. Of these 41 variants 24 are nonpathogenic SNPs 
(Table 2) and 17 of these are pathogenic mutations (Table 1). Fourteen out of 
these 17 have recently been described as a novel pathogenic mutation [7]. Two DNA 
samples, with three different known mutations in the SACS  gene, were kindly made 
available by Dr. F. M. Santorelli from Italy [6]. 
 Samples carrying a homozygous variation were mixed with a mutation-nega-
tive reference sample. All 41 variations could be detected by CSCE, except for 
two SNPs in amplicons 3 and 11, respectively. The first SNP c.172-129A>G  which 
is located just one bp next to the forward primer of amplicon 3 (exon 3), displayed 
a completely normal pattern and could not be distinguished from the reference 
pattern (Figure 1). All pattern parameters had values below the initial threshold 
settings (Table 4). 
 The pattern of the second SNP c.2080G>A at position 151 of the 488 base 
pair long amplicon 11 (exon 7) did not show a clear heteroduplex band. The pattern 
differed just slightly from the reference peak. All pattern parameter values were 
below the initial threshold settings, except for the MAX value (6.1%) which was 
just above the threshold. The CG-content of  this amplicon was 50%  which is the 
highest of all (mean, 39%). All other variants could clearly be detected regardless 
of their position in the amplicon or the CG-content of the amplicon. On duplication, 
identical results were obtained.
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Phase two (Prospective analysis):
To further assess the analytical sensitivity and to determine the analytical 
specificity of CSCE for the SACS gene, CSCE and sequencing was performed in 
parallel for all 44 amplicons (except amplicon 2) of the SACS gene in a cohort of 
20 individuals for whom mutation analysis of the  gene was requested for clinical 
purposes. In this cohort an additional 10 novel variants, including two pathogenic 
mutations (c.9911_9912del/ p.Leu3304fs and c.10442T>C/ p.Leu3481Pro) were 
detected. Four of these additional variants occurred in three additional amplicons 
that could not be assessed in the first phase, since no samples containing 
variants in these amplicons were available at that stage. All 73 variants present in 
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Figure 1  Example of initially false negative capillary heteroduplex electrophero-
gram. This electropherograms shows the analysis of amplicon 11 con-
taining the heterozygous SACS c.2080G>A variation, indicated by the 
arrow. The pattern of the sample containing the  variation and the pattern 
of the normal genotype sample are virtually identical. This variation is 
located  at nucleotide 151 of the 488 nucleotides in total. This variation 
could be detected after optimization of the threshold values of the data 
analysis software (Bionumerics). This underlines that optimization of the 
data analysis program is crucial.
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this cohort, including eleven known variants, occurring in 18 different amplicons 
(including two overlapping amplicons) could be detected by CSCE, except again 
for the SNP in fragment 11 (exon 7) which gave a false negative score. This results 
in an analytical sensitivity of  98.6% prior to further optimization of the design, and 
of 100% after optimization. This optimization includes an optimized primer design 
for amplicon 3, resulting in successful detection of SNP c.172-129A>G, and of 
relaxation of parameter settings of the data analysis program (Table 4 II), resulting 
in the successful detection of SNP  c.2080G>A in amplicon 11 (exon 7). 
 Two true false positive results were observed in two different amplicons 38 
(exon 9) (Figure 2) and 39 (exon 9) respectively, giving a false positive variant 
detection rate of 0.25% with an analytical specificity of  99.8%. 
 As all samples are mixed with PCR product of a reference sample negative for 
pathogenic SACS mutations, it cannot be determined from the raw data whether 
a DNA variant that has been detected is homozygous or heterozygous in the test 
sample. Out of 73 alterations detected, nine turned out to be homozygous variations 
after sequencing.
 Due to overlap in the amplicons, five variations have been detected in two 
consecutive amplicons (Tables 1 and 2; one example is shown in Figure 3). In 
three samples two variations per amplicon (15, 35 and 41 [exon9]) were present, 
resulting in a pattern of multiple conformational changes (cf. example in Figure 4A 
and B). The separate patterns when occurring as a single variation are displayed 
beneath for comparison.
The parameters and settings are described in the Materials and Methods section. 
Peaks indicated in green should be considered as normal and do not require 
subsequent sequencing.
CSCE-BASED MUTATION SCANNING OF SACS
4
Table 4 Peaking matching parameters
Parameter Treshold
 Green (II) Green (I) Orange Red
SRMS < 3.50 < 7.00 ↔ > 20.00
MAX < 3.50 < 6.00 ↔ > 20.00
SECPK < 200.00 < 200.00 ↔ > 400.00
DFH3 < 1.00 < 1.00 ↔ > 1.70
DFH4 < 0.70 < 0.70 ↔ > 1.20
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Green II indicates the adapted parameters. Peaks indicated in orange need 
further visual inspection and peaks indicated in red always require sequencing.
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Figure 2  Example of false positive capillary heteroduplex electropherogram 
  This electropherogram shows the true false positive result in amplicon 
38 (exon 9).
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Figure 3  Example of a variation in two overlapping fragments. Due to overlap in 
the amplicons, five variations have been detected in two consecutive 
amplicons (Tables 2 and 3). Figure 3 shows the mutation (indicated by 
the arrow) c.1475G>A in  amplicon 9 (located at nucleotide 448 of the 
484 nucleotides in total) and 10 (at nucleotide 84 of the 449 in total).
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CHAPTER 4
Figure 3  Example of two variations in a single amplicon. In three samples two 
 variations per amplicon (15, 35 and 41 (exon 9)) were present, resulting 
in a pattern of multiple conformational changes. For example figure 4A 
 (amplicon 41 (c.12160C>T and c.12304T>C)) shows multiple conforma-
tional changes as the variants are located on different alleles. The separate 
patterns when occurring as a single variation (Figure 4B) are displayed 
beneath for comparison. The arrows indicate the variations
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Discussion
DNA diagnostic service laboratories are receiving a steadily increasing number of 
requests for confirmation or exclusion of the clinical diagnosis of a particular 
genetic disease by DNA techniques. This requires efficient mutation scanning of 
disease-causing genes by techniques such as automated sequencing, denaturing 
high performance liquid chromatography, denaturing gradient gel electrophoresis, 
melting curve analysis, or CSCE. For very large genes, such as the SACS gene, 
mutation scanning is labor intensive and costly with regards to consumable use. 
Therefore it is desirable to develop alternative scanning methods which are 
reliable, rapid and inexpensive. CSCE is such a method, and here we describe in 
detail the design and analytical validation of CSCE for the SACS gene, including 
the pitfalls and difficulties encountered. 
Development and design
To design and test the use of CSCE as a fully automated scanning method for the 
large SACS gene, 52 DNA samples were used for development of optimal running 
conditions for the different amplicons, for development of optimal automated 
data analysis parameters, and for subsequent analytical validation. A first 
important conclusion we can draw from the process of developing a CSCE 
system is that the developmental and validation stages of the process have to be 
performed consecutively in clearly distinct phases. The distinction has to be 
made in order to prevent that adaptations made to the CSCE system or the 
analysis software criteria that may be necessary to make to comply with the 
performance criteria, result in a disturbed validation process. This requires the 
definition of clear and unambiguous performance criteria for the  CSCE system 
and the automated data analysis software before the development process has 
started. These a priori performance criteria are a high analytical sensitivity of at 
least 99% and an analytical specificity of at least 96% for the CSCE system. In 
addition, the robustness of the technique has to be very good (less than 5% 
failure rate) and the costs compared to automated sequencing of the complete 
coding region of the gene under study should be less than 50%.
 To detect a homozygous mutation by CSCE in an autosomal recessive condition 
such as ARSACS, DNA of the parents could in principle be used for analysis. 
However, since DNA of parents is not always available we have chosen to mix PCR 
product of a patient (test-DNA) with PCR product of a mutation- negative reference 
sample (reference-DNA). 
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In this procedure, it is very important to monitor the amount of the PCR product of 
interest on an agarose gel prior to CSCE analysis by estimating the ethidium 
bromide staining intensity to avoid aberrant results, eg, by erroneously analyzing 
just reference-DNA, or reversely unmixed test-DNA. 
 For amplicon 2 (exon 2) a different PCR mix and PCR program is used because 
of its high CG-content (75%). With CSCE no reliable results could be obtained for 
this amplicon, and therefore this amplicon is excluded from the CSCE analytical 
strategy, and directly sequenced. It has been documented previously that a very 
high or a very low CG-content reduces the sensitivity of heteroduplex methods [8]. 
 After identifying the false negative SNP c.2080G>A in amplicon 11 (exon 5) 
the lower limits of the peak matching parameters were changed into more relaxed 
parameters (Table 4). With these newly lower limit parameters the false negative 
SNP in amplicon 11 could easily be detected. The other false negative SNP 
c.172-129A>G  in amplicon 3 (exon 3) underlines the importance of designing 
primers not to close to the intron-exon boundary, as a variant which is located 
close to, and in this instructive example only one bp apart from the primer, will not 
be detected by CSCE. In our cohort the position of the variants detected ranged 
from +1 bp distance to the forward primer to 10 bp distance to the reverse primer. 
In conclusion, after adaptation of the parameters of the data analysis program, 
and redesign of the amplicons also these two false negative SNPs could be 
detected by CSCE. This results in an overall final analytical sensitivity of 100%.
 Four primers (18RP, 19FP, 20FP, 20RP) had to be redesigned, due to four 
different variants that occurred underneath the primers. Two of these are 
pathogenic mutations (c.4108C>T/ p.Gln1370X and c.4957G>T/ p.Glu1653X) and 
the other two are SNPs (c.4188C>T, c.4466A>G). These redesigned primers have 
also been tested and validated, and showed normal results. 
 In Figure 4 the capacity of the CSCE technique to detect multiple variants 
located on different  alleles in a single amplicon is shown. This could be used to 
design a strategy to discriminate a mutation from known SNPs with relatively high 
occurrence in the population by admixture of a reference fragment containing the 
particular SNP with the corresponding fragment of a patient before heteroduplex 
formation. This strategy could be extended to all amplicons containing known 
frequently occurring SNPs. By this strategy the number of additionally required 
subsequent sequencing reactions can be reduced.
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Validation 
The use of CSCE as a fully automated mutation scanning method for the large 
SACS gene has been validated. A recurrent issue in the discussion on how to 
perform a reliable validation of a DNA-variant (mutation) scanning technique is 
whether it is necessary to verify the capacity to identify the presence of a 
DNA-variant in each amplicon of the scanning system. For a rare disease such as 
ARSACS, not in all amplicons of the SACS gene a DNA-variant is known. 
Furthermore, it is virtually impossible to obtain samples containing known variants 
from other laboratories upon request. 
 To get an impression on the response rate, requests for samples containing 
known DNA variants from patients known from literature were sent out to 6 different 
laboratories, to be able to test the detection capacity of an additional 6 amplicons. 
 From just one laboratory (Dr. F.M. Santorelli) two samples containing three 
mutations in 3 different amplicons were obtained. Therefore 12 of the 44 amplicons 
could not be directly tested for their capacity to detect a DNA variant in our validation 
process. Since in the technical validation of CSCE performed in collaboration with 
the groups of Matthijs (Leuven, Belgium), Mattocks (Salisbury, UK) and Applied 
Biosystems (Inter-laboratory Diagnostic Validation of Confirmation Sensitive Capillary 
Electrophoresis), to be published in detail elsewhere, it could be shown that all DNA 
variants could be detected by CSCE when taking a number of running conditions 
into account. We concluded that an analytical validation of the CSCE technique for 
the application of the SACS mutation scanning would suffice when using identical 
running conditions, and that the analysis of eg, PCR products with artificially 
created SNPs for amplicons for which no known SNPs were available would be 
superfluous [5]. These running conditions and the recipe of the confirmation 
analysis polymer used have been summarized in Table 5 and 6, respectively. We 
could conclude that an oven temperature of 12 °C results in an optimal separation 
of heteroduplex bands here fore a specific adjustment to the ABI 3730 automated 
sequencer had to be made to set this oven temperature (Table 6).
 To assess the analytical sensitivity and the analytical specificity of CSCE for the 
SACS gene, we compared it to DNA sequencing. In the analytical validation 32 of the 
44 amplicons of the  gene could be assessed directly. Initially, two SNPs could not be 
detected. After further optimization, an overall analytical sensitivity of 100% was 
determined since all 114 DNA variants identified by DNA sequencing could also be 
identified by CSCE. The overall analytical specificity was 99.8 % as a result of two 
false positive results. Settings described in this study demonstrate the experimental 
conditions resulting in an optimal balance between sensitivity and specificity.
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However, to be safer with regard to the analytical sensitivity, and thus taking less 
risk in obtaining false negative results, the stringency of the settings could be 
relaxed, accepting the possibility of a slightly lower specificity.    
  Mismatches in heteroduplex molecules can be detected best in smaller 
fragments. We have observed that to achieve optimal sensitivity amplicons 
should have a maximum length of 500 bp [5]. However in this study we noticed 
that amplicons even longer than 500 bp can easily be analyzed by CSCE.
Buffer to run consists of 1x TTE, 10% glycerol (national diagnostic, EC-871).
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Table 5 Running conditions CSCE
Run condition Value Range
Oventemperature 12 °C 12-70 
Buffer temperature 35 °C 30-35 
Pre-run-voltage 15 kV 0-15 
Injection time 20 sec 1-90
Pre-run-time 180 sec 1-1800 
Injection voltage 3 kV 0-15 
First read out time 180 ms 100-16000 
Exposure time 0 ms 0-5000 
Run voltage 13 kV 15 
Voltage number of steps 10 kV 0-100
Voltage step interval 20 sec 0-180 
Voltage tolerance 0.6 kV 0-6
Current stability 500 mA 0-2000
Ramp delay 200 sec 1-800
Data delay 750 sec 1-1800
Run time 5200 sec 300-14000
Table 6 Recipe CAP+
CAP (Applied Biosystems, 434037) 12.67 g
Ureum (1 kg, pro analyse, Merck) 5.27 g
Sucrose (250 g, for biochem, Merck) 2.03 g
20x TTE (national diagnostic, EC-871) 1.14 g
MQ 1.72 g
89
After a generic technical intern validation of the experimental conditions of CSCE 
an oven temperature of 12 °C turned out to result in optimal separation of hetero - 
duplex bands. A specific adjustment to the ABI 3730 automated sequencer had 
to be made to set this oven temperature.
Robustness 
Initially, capillary overloading resulting in high peaks that cannot be interpreted by 
the analysis software was observed in a number of samples. This indicates that 
the DNA concentration of the samples needs to be monitored in process, and will 
be better controllable by automation of liquid handling during the amplification 
and sequencing steps. Introduction of DNA concentration monitoring and automated 
liquid handling resulted in a reduction of the failure rate to below 5%.
 In order to improve in process quality control the use of a Liz 500 size standard 
containing a DNA fragment in which a heterozygous DNA variant has been created 
has been introduced, which allows monitoring of the capillary separation capacity 
of the conformation analysis polymer.
Costs
To improve cost-effectiveness CSCE with two differently labeled primers (FAM 
and VIC) can be considered. However, in our experience the use of a single 
labeled primer (FAM) is preferable, due to translucency and interference between 
the differently labeled peaks. Furthermore, to avoid substantial differences in 
signal intensity between the differently labeled peaks, an additional effort in 
optimization would be required. 
 Roughly CSCE is, by a factor of six, cheaper compared than sequencing. As only 
those amplicons which show a divergent CSCE pattern need to be sequenced, 
instead of the entire coding sequence of the gene, a substantial cost reduction is 
achieved. If two differently labeled primers would be used the difference in costs 
compared with automated sequencing would even be a factor of 12.
 Since one of the mutations (c.12160C>T/ p.Gln4054X) has a high relative 
frequency in ARSACS patients of Dutch descent (identified either homozygously 
or heterozygously in seven of the so far 16 families identified) we are considering 
to perform a pre-screening by direct sequencing of this amplicon (41, exon 9). 
For reasons of efficiency, this will then be combined with the sequencing of 
amplicon 35 (exon 9) containing two common SNPs, with a high relative frequency, 
eg, for one of these SNPs (c.9981C>T) both reference samples V3 and V4 are 
heterozygous.
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Mutation spectrum 
So far we have performed mutation analysis of the SACS gene in 76 index patients. 
In total 16 novel pathogenic mutations were identified in 16 different families consisting 
of 23 patients. In the remaining 60 index patients no mutations were identified, 
which most likely reflects the fact that they have a different genetic condition. 
Most mutations (13)  identified are truncating mutations, and three are missense 
mutations. Furthermore 36 different SNPs were identified of which one is a very 
common SNP (c.9981C>T) with an estimated minor allele frequency of  0.37. 
 Large deletions of the SACS gene as identified in a Belgian ARSACS patient 
[9] will be missed by both CSCE and sequencing. Therefore in the near future an 
MLPA-test for the SACS gene will be set up.
Conclusion 
Based on the various locations of the 52 variations in 32 different amplicons with 
different fragment lengths, and different CG-content our results show a high 
sensitivity (~ 100%) and specificity (99.8%) for the use of CSCE as a mutation 
scanning method for DNA variant identification of the SACS gene.
 Our recommendation would be to perform sequence analysis of all amplicons 
with divergent peaks (orange or red) after CSCE and to perform direct sequence 
analysis of all amplicons with common SNPs with a high minor allele frequency 
(eg, over 0.25) in the population.
 We can conclude that CSCE is a robust technique with a high sensitivity and 
specificity, and is highly suitable for application in mutation scanning for large 
genes such as the SACS gene.
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Targeted next generation sequencing of a 12.5 Mb  
homozygous region reveals ANO10 mutations in  
patients with autosomal recessive cerebellar ataxia.
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Abstract
Autosomal recessive cerebellar ataxias comprise a clinically and genetically 
heterogeneous group of neurodegenerative disorders. In contrast to their 
dominant counterparts, unraveling the molecular background of these ataxias 
has proven to be more complicated and the currently known mutations provide 
an incomplete coverage for genotyping patients. By combining SNP array-based 
linkage analysis and targeted resequencing of relevant sequences in the linkage 
interval using next generation sequencing technology, we identified a mutation in 
a gene and have shown its association with autosomal recessive cerebellar 
ataxia. In a Dutch consanguineous family with three affected siblings a 
homozygous 12.5 Mb region on chromosome 3 was targeted by array-based 
sequence capture. Prioritization of all detected sequence variants led to four 
candidate genes one of which contained a variant with a high base pair 
conservation score (phyloP score 5.26). This variant was a leucine-to-arginine 
substitution in the DUF 590 domain of a 16K transmembrane protein, a putative 
calcium-activated chloride channel encoded by anoctamin 10 (ANO10). The 
analysis of ANO10 by Sanger sequencing revealed three additional mutations: a 
homozygous (c.1150_1151del [p.Leu384fs]) mutation in a Serbian family and a 
compound heterozygous splice-site mutation (c.1476+1G>T) and a frameshift 
mutation (c.1604del [p.Leu535X]) in a French family. This illustrates the power of 
using initial homozygosity mapping with next-generation sequencing technology 
to identify genes involved in autosomal recessive diseases. Moreover, identifying 
a putative calcium-dependent chloride channel involved in cerebellar ataxia adds 
another pathway to the list of pathophysiological mechanisms that may cause 
cerebellar ataxia.
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Autosomal recessive cerebellar ataxias are a heterogeneous group of rare neuro-
degenerative disorders in which progressive spinocerebellar ataxia, due to 
involvement of the cerebellum, brainstem and/or spinocerebellar long tracts, is 
the key feature. Clinically, patients are characterized by gait and balance 
impairment, upper limb coordination problems, and impairment of speech, 
swallowing and eye movements. The overall prevalence is estimated to be around 
five to six per 100,000 [1]. Autosomal recessive cerebellar ataxias are often 
associated with other neurological (e.g., polyneuropathy, spasticity) or non-neu-
rological (e.g., cardiomyopathy, cataract) symptoms and can thus lead to complex 
phenotypes. Most autosomal recessive ataxias have an early age of onset, 
formerly defined as < 20 years of age [2], but some have been shown to begin 
much later. In contrast to the rapidly increasing number of genes involved in the 
autosomal dominant cerebellar ataxias, the molecular background of the 
recessive cerebellar ataxias has been only partly elucidated. Many patients with 
a recessive ataxia are therefore still left without a molecular diagnosis.   
 Here, we describe the identification of a gene involved in autosomal recessive 
cerebellar ataxia, with downbeat nystagmus and involvement of lower motor 
neurons as additional clinical features. The gene was identified in a Dutch 
remotely consanguineous family (Figure 1A).  The current study was approved by 
the Medical Ethics Committee of the Radboud University Nijmegen Medical 
Centre. Written informed consent to participate in the study was obtained from 
the patients and their participating relatives (and all other patients described in 
this paper). All three affected siblings from this family displayed impaired 
coordination of limbs and gait with an onset between 20 and 35 years. Neurological 
investigation revealed a gaze-evoked downbeat nystagmus with hypermetric 
saccades, dysarthric speech and brisk knee reflexes. Mild atrophy of the upper 
part of the lower limbs with fasciculations was observed in two of the three 
affected siblings. These two also had evidence of lower motor neuron involvement 
on electromyography (Table 1). In all 3 affected siblings, brain imaging displayed 
marked cerebellar atrophy with normal supratentorial structures (Figure S1).
 Homozygosity mapping using a 10K SNP array identified five homozygous 
regions on chromosomes 3, 6, 10, 12, and 16. Only the region on chromosome 3 
was confirmed by further fine-mapping with short tandem repeat markers, which 
showed a locus of approximately 10.5 Mb on chromosome 3p21.32-p22.3 with a 
LOD score of 3.6 in this Dutch family. This locus could be further confirmed and 
fine- mapped by using a 6.0 SNP array (Affymetrix), interrogating over 900,000 SNPs. 
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The multipoint LOD score calculations and haplotype analysis were performed 
with GeneHunter (version 2.1 release 5.05) in the easyLINKAGE software package 
and Haplopainter software. Within the major locus more than 80 genes are 
located, of which 15 candidate genes were sequenced by traditional Sanger 
sequencing, selected on the basis of their known function and cerebellar 
expression. No mutations could be identified in these genes. Subsequently, we 
targeted the entire 12.5 Mb region on chromosome 3 as well as nine smaller 
homozygous regions on chromosomes 1, 2, 3, 4 and 14, for array-based sequence 
capture  followed by next-generation sequencing (Table S1a ). 
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Figure 1  Identification of ANO10 Mutation in the Dutch Family A with Autosomal-
Recessive Cerebellar ataxia. 
  (A) Pedigree for the Dutch family A together with the segregation of the 
mutation identified in this family. M1/M1 indicates  homozygous car-
riers of the p.Leu510Arg mutation, and M1/+ indicates heterozygous 
carriers. The proband is indicated by the arrow. Unfortunately, DNA 
was not available for the individual A:V.3.
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Figure 1  Continued. 
  (B) Coverage histogram of ANO10. Upper part: Sequence-read histo-
grams uploaded to the UCSC Genome Browser display the sequenc-
ing depth of all exons of ANO10. Tracks displayed: scale, chromo-
somal position, read depth histogram per bp (between 0 and 60-fold 
coverage; higher than 60-fold is not displayed), RefSeq gene track, 
highly conserved elements (Phast Cons Placental Mammal Conserved 
Elements, 28-way Multiz Alignment). Lower part: Next-generation 
sequencing-read coverage of ANO10 exons 8-10. Tracks displayed: 
scale, chromosomal position, individual 454 sequencing reads, Ref-
Seq gene track. (C) Mutation visualization in the IGV browser. Individ-
ual reads overlapping with the mutation are displayed. Seventeen of 
eighteen reads show the homozygous mutation at genomic position 
chr3: 43571913 (the reads are mapped and displayed on the + strand).
B
C
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Figure 1  Continued. 
  (D) Verification by Sanger sequencing of missense mutation c.1529T>G 
(p.Leu510Arg) in ANO10 (accession number NM_018075.3). (E) Sequence 
comparison of the ANO10 in different species. The amino acid that is 
mutated in the Dutch family is depicted, indicated by an arrow. The 
amino acid is highly conserved throughout different species, including 
the fruit fly.
D
E
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The array design included all known exons, untranslated regions (UTRs), 
microRNAs, and highly conserved regions (PhastCons Conserved Elements, 
28-way MostCons Plac Mammal Multiz Alignment, LOD score ≥ 100) for all 
homozygous regions [3, 4]. An additional 30 base pairs (bp) sequences flanking 
all exons were added to the regions that were captured on the array to enable the 
detection of splice-site mutations. Targets smaller than 250 bp, which is, based 
upon our experience, the minimum size for the DNA capture protocol used, were 
enlarged by extending both ends of the region. The targeted sequences comprise 
1,905,376 bp in total (Table S1b), and include 1245 exons from 117 RefSeq genes 
and 187 UCSC genes (see Web Resources), as well as 7 microRNAs and 
noncoding RNAs. After stringent probe selection by NimbleGen (Roche 
NimbleGen, Madison, WI, USA) (uniqueness tested by Sequence Search and 
Alignment by Hashing Algorithm [SSAHA]), a total of 2,178,492 bases (Table S1c) 
were represented on an array, with 385,000 oligonucleotide probes targeting the 
regions of interest. Sequence capture was performed in accordance with the 
manufacturer’s instructions (Roche NimbleGen), with the use of the Titanium 
optimized protocol. In brief, 5 µg of genomic DNA of the proband (Figure 1A) was 
used in the preparation of the DNA library for sequence-capture hybridization. A 
final amount of 3 µg prehybridization ligation-mediated-PCR-amplified DNA was 
hybridized to the customized array, eluted after 72 hours of hybridization, and 
amplified by post-hybridization  LM-PCR. The amplified captured sample was 
then used as input for emulsion PCR amplification and subsequent sequencing 
using a Roche 454 GS FLX sequencer with Titanium series reagents. 
 The sample was sequenced by using one-quarter plate of a Roche sequencing 
run, yielding 83.7 Mb of sequence data. Approximately 95.0% of the sequence 
data mapped back to unique regions of the human genome (hg18, NCBI Build 
36.1), with the use of the Roche Newbler software (version 2.3). Of all mapped 
reads, 93.5% were located on or near the targeted regions (i.e., within 500 bp 
proximity) (Table S2). This was sufficient to reach an average of 32-fold coverage 
for all target regions. For the region of interest, less than 1% of all targeted 
sequences were not covered, and only 4.2% of the target sequence was covered 
fewer than ten times (11% was covered less than 15-fold). 
 The Roche software detected a total of 3917 high-confidence variants, 
identifying the variant in at least 3 reads. We used a custom-made data analysis 
pipeline as described by Hoischen et al.[5] to annotate detected variants with 
various types of information, including known SNPs, amino acid substitutions, 
genomic location, and evolutionary conservation. 
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Table 1  Clinical features of patients with recessive cerebellar ataxia with  
mutations in ANO10 
Patient A:VII.1 A:VII.2 A:VII.3 B:II.3 B:II.4 B:II.5 C:II.1 C:II.3
Age 50 48 47 42 39 35 60 55
Sex  M M F F F M F F
Age of onset (yr) 25 20 32 15 15 13 45 25
Age at assessment 50 48 47 42 39 35 57 49
Mental retardation No No No Yes (mild) Yes (moderate) No No No
Ocular pursuit
 
Downbeat 
nystagmus
Downbeat nystagmus
Downbeat 
nystagmus
Horizontal 
and vertical 
nystagmus
Horizontal and 
vertical nystagmus
Horizontal 
nystagmus
Saccadic pursuit, 
nystagmus
Multidirectional 
nystagmus
Saccades
 
Hypermetric
Hypermetric, slow 
(vertical)
Hypermetric Hypermetric, mild No Hypermetric, mild No Slow saccades
Cerebellar  dysarthria Moderate Moderate Mild Moderate Mild Moderate Moderate Moderate
Gait ataxia Moderate Moderate Mild Moderate Moderate Moderate Severe Moderate
Appendicular ataxia
 
Moderate Moderate Mild Mild Mild Mild Moderate Moderate
Tendon 
reflexes
UL Increased Increased Increased Increased Increased Increased triceps Increased Increased
LL
knee Increased Increased Increased Increased Increased Increased Increased Increased
ankle Increased Normal Increased Increased Normal Normal Increased Increased
Plantar responses
Extensor Normal Normal Normal Normal Normal Normal Normal/ Babinski
Other 
features
 
Cold and blue 
toes
Wasting and 
fasciculations 
proximal leg muscles, 
cold and blue fingers 
and toes
Cold and blue 
fingers and toes
Inspiratory stridor Pes cavus
Fasciculations 
leg muscles. 
Inspiratory stridor 
and vocal cord 
paresis
Mild lower limb 
spasticity, slight 
rest tremor, pes 
cavus
Episodic 
diplopia, pes 
cavus
EMG
 
Motor neuron 
involvement
Motor neuron 
involvement
Not done Not done Not done
Motor neuron 
involvement
Not done Normal
Cerebellar atrophy  
on MRI/ CT
Severe Severe Severe Severe Severe Severe Not done Severe
Tortuosity of  
conjunctival vessels
Absent Absent Absent Present Present Present Absent Absent
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A total of 3352 variants were found to correspond to known SNPs and 169 variants 
overlapped with a known polymorphic region (dbSNP130) and were therefore 
considered not likely to be disease-causing variants. Of all remaining 396 variants, 
there were three potential splice-site variants, two synonymous coding variants, 
and five nonsynonymous coding variants, of these ten variants only four  were 
called as homozygous variants (i.e., >80% variant reads) (Table S2 and S3). Of 
the four remaining candidates, only two variants were conserved during evolution 
[6], one of which had previously been reported in our internal variant database in 
a patient with a different disorder. 
 The remaining single candidate was a homozygous T>G change in ANO10 
that was highly conserved (phyloP score 5.26) and also scored high on the 
Grantham scale (145) (Table S3). 
 ANO10 consists of 13 exons of which 12 are coding, spanning 2734 base 
pairs and 660 amino acids (NM_018075.3). All exons of ANO10 were covered by 
sequence reads from the targeted next-generation sequencing experiment 
(Figure 1B). The homozygous T>G change at position 1529 that was detected by 
next-generation sequencing occurred in exon 10 and is predicted to result in an 
amino acid substitution of leucine by arginine at codon  510 (p.Leu510Arg). The 
mutated nucleotide (at position g.43,571,913; hg18, NCBI Build 36.1) was covered 
by 18 unique sequence reads. In 17 reads, the mutant allele was detected, 
indicating that the mutation is present in a homozygous state (Figure 1C). The c. 
1529T>G (p.Leu510Arg) mutation was confirmed by conventional Sanger 
sequencing and cosegregated with the disease in this family (Figures 1A and 1D). 
The mutation was not present in over 300 control alleles (Table 2). This residue is 
conserved across multiple vertebrate species (Figure 1E) and is located in the 
DUF590 domain, a domain of unknown function.
 Next, we analyzed this gene by conventional Sanger sequencing in a 
consanguineous family (family B) with three affected siblings of Romani ethnic 
origin from Serbia (primer sequences are listed in Table S4). In family B an 
independent linkage analysis was performed, and the candidate region 
overlapped with the whole region in the Dutch family initially studied (data not 
shown). A homozygous 2 bp deletion (TT) at position 1150 (c.1150 _1151del) was 
identified, leading to a frameshift (p.Leu384fs) in exon 6 (Table 2). This frameshift 
mutation cosegregated with the disease in this family (Figure 2) and introduces a 
stop codon at position 474. The mutation was not present in the dbSNP130 
database, and was not detected in over 300 control alleles. The affected siblings 
in this second cerebellar ataxia family also manifested tortuosity of conjunctival 
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vessels and intellectual disability in two siblings (Table 1). Furthermore, ANO10 
mutation analysis was performed in a large cohort of 282 index patients with 
cerebellar ataxia with presumable autosomal-recessive inheritance. In most patients 
of this cohort, Friedreich ataxia (FA [MIM 22930]) had already been excluded by 
mutation analysis of FRDA. 
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Figure 2  Pedigree structure of  two additional families, B and C.
  Pedigrees for family B, from Serbia, and family C, from France, togeth-
er with the segregation of the mutations identified in these families. 
M2/M2 indicates homozygous carriers of the p.Leu384fs mutation, 
and M2/+ heterozygous carriers, whereas +/+ indicates individuals 
with two wild-type alleles. M3/M4 indicates compound heterozygous 
carriers for the c.1476+1G>T and the p.Leu535X mutations, and M4/+ 
indicates heterozygous carriers for the p.Leu535X mutation. For family 
B, the degree of consanguinity is not known. Unfortunately DNA was 
not available for the individual C:I.1.
B:I.1 B:I.2 B:I.3
M2/+
B:I.4
B II.2:
+/+
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Two compound heterozygous mutations, a splice-site mutation in exon 9 (c.1476+ 
1G>T), and a nonsense mutation in exon 10 (c.1604del: p.Leu535X), were identified 
in a single family (family C) with two affected siblings of French descent (Figure 2). 
The phenotype of these patients is almost identical to the phenotype of the Dutch 
family (Table1). An overview of the mutations identified in ANO10  is presented in 
Table 2.  So far, we have identified 29 different SNPs in this gene.
In adult tissues, ANO10 has the highest expression in brain as shown by quantative 
PCR (qPCR) (Figure 3A). Medium expression levels were found in the retina and 
heart, and low expression levels were found in other tissues tested. Comparing 
the ANO10 expression levels between several adult brain areas showed the 
highest expression levels in the frontal and occipital cortices and in the cerebellum 
(Figure 3B). In addition, we found that the expression of ANO10 in the fetal brain 
is lower than in the adult whole brain, indicating a specific function for ANO10 in 
adult mature brain and especially in the cerebral cortex and the cerebellum, rather 
than in brain development, although a role of this gene in brain development 
cannot be excluded. The expression profile is consistent with the relatively late 
onset of ataxia. However, ANO10, as well as ANO2 [MIM 610109] and  ANO8 [MIM 
610216], were detected with similar distributions in the mantle layer of the neural 
tube and in the dorsal root ganglia at embryonic day 14.5 in murine embryos [7]. 
Furthermore, expression studies during cephalic development in the mouse 
seems to show embryonic expression of ANO10 during brain development [8].
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Table 2 Overview of the mutations identified in  ANO10
Family Proband
No. of 
affected 
siblings  
with the 
mutation
Mutations  
(cDNA level)
Mutation  
(protein level)
Frequency 
in control 
alleles
Family A VII.1 2 c.1529T>G / c.1529T>G p.Leu510Arg (homo) 0/300
Family B II.5 3
c.1150_1151del / 
c.1150_1151del
p.Leu384fs (homo) 0/300
Family C II.3 2
c.1476+1G>T / 
c.1604del
a / p.Leu535X (hetero) 0/300
a The effect of the splice-site mutation at the protein level has not been studied
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ANO10, also known as TMEM16K (transmembrane 16K), is a member of the 
human anoctamin (ANO) family which comprises at least nine other proteins, all 
exhibiting eight transmembrane domains and a DUF590 domain of unknown 
function [9, 10]. Only very recently, it was proposed that some or all of the 
anoctamin genes code for cell- and tissue-specific calcium-activated chloride 
channels [11-13]. 
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Figure 3  Expression of ANO10 in different human tissues, seen qPCR.
  (A) Expression of ANO10 in different adult tissues, with the highest 
 expression seen in brain. (B) Expression of ANO10 in different brain 
 tissues, with the highest expression seen in adult cerebellum and 
 frontal and occipital cortices.
A
B
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In murine tissues, ANO10 is predominantly expressed in epithelial cells next to 
ANO1 [MIM 610108], ANO6 [MIM 608663], ANO7 [MIM 605096], AN 8, AN 9 , 
while ANO2, ANO3 [MIM 610110], ANO4 [MIM 610111] , and ANO5 [MIM 608662] 
expression seem common in neuronal and muscle tissues. On the basis of results 
of the functional studies done by Schreiber et al., it appears likely that  different 
anoctamins  interact with each other [11].
 It is known that calcium-activated chloride channels have important physiological 
functions, including, among others, regulation of neuronal excitability [14]. Whether 
ANO10 really codes for a calcium-regulated chloride channel remains to be 
confirmed. In the phylogenic tree of anoctamin genes, ANO1 is the member most 
distant from ANO10. A total of ~25 amino acids are missing from the region 
coding for the reentrant loop between TM5 and TM6 in ANO10, compared to 
ANO1 [10], possibly blocking the proper formation of a channel. It is also possible 
that the ANO10 product can only function in combination with other anoctamins 
to form heteromeric channels. Notwithstanding this, it is tempting to speculate 
that ANO10 indeed encodes a (subunit of) a calcium-regulated chloride channel. 
Deranged calcium signaling in Purkinje cells is one of the major mechanisms 
causing cerebellar ataxia [15, 16]. Several products of known ataxia-associated 
genes, such as calcium pumps and voltage-gated sodium or potassium channels, 
may increase or dampen calcium-signaling pathways in Purkinje cells [17-20]. It 
could well be that the ANO10  product, which is postulated to be a calcium-de-
pendent chloride channel, is also a player influencing calcium signaling in 
Purkinje cells, and a dysfunctional or absent ANO10  product may cause cerebellar 
ataxia via this mechanism. The identification of a putative chloride channel 
involved in a relatively pure, non-episodic cerebellar ataxia may thus shed new 
light on the pathological mechanisms leading to cerebellar degeneration. 
Different molecular pathways, such as mitochondrial and DNA repair dysfunction, 
are already known to be involved. As mentioned, in autosomal-dominant 
cerebellar ataxias, involvement of calcium, sodium and potassium channels has 
been demonstrated [19, 21, 22]. However, to our knowledge the involvement of a 
(calcium-activated) chloride channel in a cerebellar neurodegenerative disease 
has not yet been reported. Chloride channels are known to be involved in other 
diseases such as myotonia congenita (MIM 160800 and 255700), Dent disease 
(MIM 300009), cystic fibrosis (MIM 219700) and  Bartter syndrome (MIM 602522) 
[23-26]. At present however, the basic function of ANO10 is poorly understood, 
and so far most functional studies of anoctamins have been performed with 
ANO1.  
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 Dominant mutations in ANO5 (also known as GDD1) have been associated 
with a rare skeletal disorder called gnathodiaphyseal dysplasia (GDD [MIM 
166260]) [27]. 
Recently, recessive mutations in ANO5 have been identified in patients with limb 
girdle muscular dystrophy type 2L (LGMD2L [MIM 611307]) and distal non-dysferlin 
Miyoshi myopathy (MMD3 [MIM 613319]) [28]. So far, no other members of the 
anoctamin gene family have been associated with genetic diseases in human. 
In conclusion, we have identified mutations in ANO10 associated with autosomal-
recessive cerebellar ataxia. This report illustrates that the combination of 
homozygosity mapping together with targeted array-based sequencing is a 
powerful tool for identifying causative genes for autosomal recessive diseases. 
Mutations in ANO10 have so far been identified in three different families, with a 
total of eight patients, originating from the Netherlands, Serbia and France. The 
phenotype of the patients is fairly similar (Table 1). Additional functional studies 
are to be awaited in order to understand how dysfunction of the ANO10-encoded 
putative chloride channel results in cerebellar ataxia. 
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Figure S1  Magnetic Resonance Imaging of One of the Affected Patients Dis-
playing Marked Diffuse Cerebellar Atrophy on Both Saggital (Upper 
Picture)  and Axial  (Lower Picture) Images.
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Table S1  Targeted Regions of the Array Analysis
1a  Targeted regions
Chromosome start end size
Chr.1 77,105,773 78,116,669 1,010,896
Chr.1 91,918,489 93,199,672 1,281,183
Chr.2 140,705,465 142,605,740 1,900,275
Chr.3 17,173,658 17,869,885 696,227
Chr.3 32,123,105 33,009,854 886,749
Chr.3 34,355,326 44,599,977 10,244,651
Chr.3 78,729,077 80,456,380 1,727,303
Chr.3 126,284,169 127,489,262 1,205,093
Chr.3 131,245,012 131,313,041 68,029
Chr.4 147,394,586 147,692,007 297,421
Chr.14 59,132,446 59,624,078 491,632
Sum 19,809,459
1b  Base pairs targeted 
Total bp targeted 
1905376
1c  Total base pairs targeted after probe selection  
Total bp tiled 
2178492
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Objectives obtained
The main objectives of the research described in this thesis were to improve the 
diagnostic process and genetic counseling of patients with autosomal recessive 
cerebellar ataxias (ARCAs), unravel novel  genetic causes for these disorders, and 
link these causes to specific phenotypic characteristics. 
To improve the diagnostic process, we designed a comprehensible guideline for 
phenotype-guided genetic testing  (table 5 in Chapter 1) based on an extensive 
review of  the clinical phenotype and, genetic etiology of the different ARCAs 
known to date, combined with our own new genetic and phenotypic data on 
autosomal recessive cerebellar ataxia of Charlevoix-Saguenay (ARSACS)(Chapter 3 
and 4), and ARCA3 (Chapter 5).  For this latter form of ARCA, we were able to identify 
the genetic cause using a new and highly efficient strategy that became available 
during the course of our studies: targeted next generation sequencing (NGS; 
Chapter 5). This finding adds a novel gene to the list of already known genes 
involved in ARCAs.  All together,  the data obtained in this study will be of benefit 
in genetic counseling for a growing number of ARCA patients. 
In this chapter, I will discuss the results of my study in more detail, highlight its 
implications and limitations and focus on the future challenges for research and 
diagnostics of ARCAs.  
PMM2-Congenital Disorder of Glycosylation
Chapter 2 describes two patients with an ARCA phenotype who turned out to 
have the rare metabolic disease PMM2-CDG. Moreover, both  patients displayed 
a normal plasma transferrin profile whereas in general an abnormal isofocussing 
profile of plasma transferrin points to the diagnosis of CDG. Therefore the 
measurement of phosphomannomutase activity in leukocytes should be 
considered if transferrin isofocussing is normal in patients suspected of having 
an ARCA with cerebellar hypoplasia on neuroimaging, who have no (genetic) 
diagnosis after a proper work-up.
ARSACS-phenotypic and genetic analyses 
Our study is the first and most systematic genetic and clinical characterization of this 
disorder in the Dutch population (Chapter 3). 
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We have proven ARSACS to be a common genetic cause of ARCA in the 
Netherlands and we showed that ARSACS is clinically characterized by a distinct 
and uniform phenotype. The high rate of mutations (37%) we have identified in a 
selected group of Dutch patients with cerebellar ataxia, indicates that ARSACS is 
much more frequent in the Netherlands than previously assumed. 
 After the initial study described in chapter 3, we have tested more patients 
with cerebellar ataxia for mutations in SACS.  So far, we have identified 28 (index) 
patients with SACS mutations among 232 (index) patients. Fifteen of these 
ARSACS patients originate from the Netherlands. Table 1 gives an updated 
overview of all different pathogenic mutations identified in SACS so far.  The total 
percentage of patients with ARSACS in this cohort of initially genetically 
undiagnosed ARCAs is 12%. This is in line with the recently established prevalence 
(14%) of ARSACS among a cohort of Belgian patients with cerebellar ataxia, as 
reported by Baets et al.[1].  
 Furthermore, our detailed clinical  study revealed a characteristic core 
phenotype, consisting of cerebellar ataxia and severe spastic paresis of the lower 
limbs and peripheral neuropathy with cerebellar atrophy shown by neuroimaging, 
in all our ARSACS patients, similar to what has been described for ARSACS in 
literature [2-7]. However, it should be noted that in contrast to what was stated in 
Chapter 3, screening of SACS also seems appropriate in patients with the core 
phenotype and a later onset, as illustrated by the cases described by Baets et al. [1]. 
 So far only three mutation-proven ARSACS patients with an unusual phenotype 
have been described [1, 8, 9]. However, the two patients described by Shimazaki 
with absence of lower limb spasticity both displayed bilaterally Babinski signs 
indicating pyramidal involvement; here the spasticity was likely masked by the 
severe neuropathy. In addition, the lack of clinical or electrophysiologic signs of 
peripheral neuropathy in the third patient, of the Belgian cohort, might be due to 
the very late onset (40 yrs) of the disease. This might be the reason why the 
peripheral neuropathy has not yet evolved. 
 Overall, ARSACS is a genetically and clinically homogeneous disorder that 
can be recognized by clinicians, within an otherwise highly heterogeneous total 
group of ARCAs. Thus, recognition of the distinct ARSACS phenotype improves 
the diagnostic process since it allows targeted DNA testing. Moreover, it is likely 
that additional ARSACS patients will be identified when routine diagnostic 
screening of SACS is performed in selected patients with the following triad of 
symptoms: cerebellar ataxia, spastic paresis of the lower limbs and neuropathy, 
in whom FA has been excluded. The question remains whether targeted DNA 
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testing will be the future. With the availability of new techniques, such as NGS it 
will soon be much more time and cost efficient to directly perform exome 
sequencing, which sequences all coding genes  in one experiment  instead of 
sequencing gene after gene. As costs drop further it will eventually be standard 
practice to use exome sequencing for diagnostic purposes in all patients with a 
suspected genetic disorder including ARCA. 
 Additionally it is important to know that ARSACS patients, with a slightly 
different phenotype consisting of  hearing loss and learning difficulties, have 
been described with a microdeletion on 13q12.12 encompassing SACS (and a 
mutation on the other allele). This underlines the need for additional mutation 
detection techniques besides conventional Sanger sequencing [10, 11]. For 
example, multiple ligation probe amplification (MLPA) or as mentioned before 
NGS based techniques. Thus far, in our DNA diagnostic laboratory ARSACS 
patients with (multiple) exon deletions of SACS or microdeletions encompassing 
SACS have not been identified. 
ARSACS - Sacsin
So far, not much is known about the exact function of the protein sacsin, involved 
in ARSACS. It is known to contain a functional J-domain and a ubiquitin-like 
domain suggesting that sacsin may play a specific cellular role linking the ubiqui-
tin-proteosome pathway to the heat shock protein 70 machinery for processing 
and folding of proteins [30]. To further elucidate the exact function of this protein 
and its role in the pathophysiology of ARSACS we have started a collaboration 
with our Department of Pathology (Dr. B. Kusters, pathologist) and the William 
Harvey Institute in London (Dr.P. Chapple, working on the biology of molecular 
chaperones). It is speculated that sacsin plays a role in mitochondrial function. 
Further studies need to confirm this. As we have brain tissue of two deceased 
ARSACS patients we want to research this further.
ARSACS - mutation scanning
By designing a heteroduplex analysis system using conformation sensitive 
capillary electrophoresis (CSCE) for mutation scanning of SACS we have 
significantly improved the efficiency of DNA diagnostics for ARSACS (Chapter 4). 
The rapid development and implementation in DNA diagnostics of new techniques, 
such as next generation sequencing, which enables massively parallel sequencing 
of many ataxia genes simultaneously, has made CSCE already redundant [31].
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Identification of a novel ARCA gene (ARCA3)
All our objectives have been reached  by identifying a novel gene (ANO10)  involved 
in an ARCA, now named ARCA3.
 In our search for new genes involved in ARCA, we started gathering (consan-
guineous) families with multiple affected siblings for homozygosity mapping. 
Homozygosity mapping is a powerful method to localize genes involved in 
autosomal recessive diseases. This technique assumes that affected offspring 
co-inherit two identical copies of a disease-related chromosomal segment from a 
common ancestor [32, 33]. 
 However, with homozygosity mapping, depending on the degree of consan-
guinity, various homozygous regions that are not related to the disease will also 
be detected, as illustrated below. It is known that the percentage of a genome 
that is homozygous or identical by descent of the progeny of consanguineous 
union with first cousin parents is 6.25% and smaller or equal to 0.4% with third 
cousin parents [33]. However, it is likely that the homozygous region spanning the 
disease locus is identical in all affected siblings and not present in unaffected 
siblings.
 By using a SNP-array we identified a locus on chromosome 3 in a consan-
guineous family with three affected siblings. In a time-frame of two years we 
sequenced 15 candidate genes, selected on the basis of their known function 
and cerebellar expression, and even started sequencing candidate genes in 
smaller homozygous regions. 
 Furthermore, we performed a whole genome exon expression array to detect 
differentially regulated splice variants or transcripts. The core set of this exome 
consists of roughly 18,000 well annotated genes and transcripts. 
 We compared the expression level of the different genes located in the locus 
in leukocytes of two affected siblings and an unaffected sibling and the mother. 
We assumed a loss of function mutation mechanism and therefore we looked for 
genes with a differential expression below 1.8 SD with p<0.05. No statistically 
significant changes could be identified. These efforts thus failed to identify the 
responsible disease gene.  Eventually, by using targeted next generation-based 
resequencing in the homozygous region on chromosome 3 we were able to 
identify the mutated gene (ANO10) within two weeks (Chapter 5). This finding, as 
well as other recent published work by the department of Human Genetics at the 
Radboud University Nijmegen Medical Centre (RUNMC), illustrates that the use of 
NGS enables amazingly rapid identification of novel disease-causing genes 
[34-36]. Being successful is not only depended on having access to these novel 
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techniques but it is also essential to identify additional unrelated patients, e.g. by 
sharing information with other researchers, as exemplified by this study. The 
identification of the two additional families with ANO10 mutations (c.1150_1151del, 
c.1476+1G>T and c.1604del) was only possible through collaboration with the 
European SPATAX network. This network aims to elucidate the molecular basis of 
cerebellar ataxias and spastic paraplegias by combining the experience and 
sample collections of European clinicians and scientists working on these disorders. 
ARCA3 - Anoctamin
ANO10 encodes TMEM16K, which belongs to the anoctamin/TMEM family of 
transmembrane proteins. Within this family, currently 10 members have been 
identified. The first two (TMEM16A and TMEM16B) have been shown to function 
as calcium-activated chloride channels [37-40]. However, it is still unclear whether 
all family members are, in fact, anion channels. Patch clamp studies performed 
at the Department of Physiology of the RUNMC have not been able to confirm 
TMEM16K to be a chloride channel. A patch clamp technique can be used to 
study ion channels in a cell, by recording the electrical activity of small areas of 
the membrane so that the effects of opening and closing of ion channels can be 
observed [41]. 
 Furthermore, by performing a western blot using an antibody for ANO10, we 
could show expression of ANO10 in cerebellum (Figure 1). So far ,we do not under - 
stand the physiological function of this protein in normal cerebellar functioning 
nor its pathophysiological involvement in ARCA. Future analysis, such as down-
regulation of ANO10 in Drosophila and knock-out mice should unravel the function 
of this gene. Eventually this may shed new light on the pathophysiological 
mechanisms involved in cerebellar ataxia.
Clinical implications  
The results of this project  have expanded the possibilities for pre- and postnatal 
diagnosis and for genetic counseling in families with ARCA (Chapter 3 and 5). 
Due to the large clinical overlap between the different cerebellar ataxias it is often 
difficult to make a correct diagnosis based on clinical details only. In the early 
days, most patients with ARCA with a FA-like phenotype were clinically diagnosed 
with FA. This is also the case for a few patients in our studies who were thought 
to have FA but turned out to have mutations in SACS or ANO10. 
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 A clear diagnosis is important for the patient and their relatives and allows better 
prognostic information and more focused follow-up of a patient. For instance, cardiac 
screening is unnecessary in patients diagnosed with ARSACS, but for patients with 
FA it is essential due to a high risk of developing cardiomyopathy [42]. 
 Although mutations in ANO10 that result in ARCA3 are probably extremely 
rare (so far we screened 321 patients for mutations in ANO10 and identified 
mutations in 5 index patients (in total 10 patients, Table 2 ), the implications of 
these findings are very relevant for the patients and their family members. This is 
illustrated by the following email correspondence of a family member of one of 
the patients with mutations in ANO10: “ Interesting to read how the mutation was 
identified. To me the counseling concerning the heredity of the disease concerning 
my father was a relief. Notably,  earlier a neurologist suggested an autosomal 
dominant inheritance”. 
 The identification of more patients with mutations in ANO10 will eventually 
give insight into the diversity of the phenotype and the details of genotype- 
phenotype correlations. 
CHAPTER 6
Figure 1  Western blot showing expression of ANO10 exclusively in cerebellum.
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Future perspectives
In the following sections the possible future developments concerning the 
diagnostics process and  the therapeutic potential related to ARCA are discussed.
Furthermore, the relevance of the ataxia protein-protein network (Ataxia-ome) 
and of international epidemiological studies are discussed.
Diagnostic process
Although the guideline for phenotype-guided genetic testing (Chapter 1) of ARCA 
patients will be of use for the present medical practice, it is to be foreseen that 
the  diagnostic work-up of an ARCA patient will soon change dramatically. 
 In the very near future exome sequencing or even whole genome sequencing 
will become the first diagnostic procedure to be performed in any patient with a 
presumed genetic disorder. Ideally, the procedure should be as follows; a patient 
is seen by a specialized neurologist and clinical geneticist at an academic  multi-
disciplinary outpatient clinic, and exome sequencing will be discussed with the 
patient. After having obtained  informed consent, exome sequencing will be 
performed. The results of the test will be interpreted along with the clinical 
 characteristics of the patient by a molecular geneticist and a clinical geneticist. 
The data will then be explained to the patient by the clinical geneticist and  (in this 
case) the neurologist. If necessary “re-phenotyping” can be done. More likely however 
is that soon non-academic medical doctors will also start applying for this test. 
GENERAL DISCUSSION
6
Table 2  Overview mutations ANO10.
Variant
Predicted protein 
change
Predicted consequence
Mutation 
type
c.132dup p.Asp45fs
Premature termination 
codon Duplication
c.1150_1151del p.Leu384fs
Premature termination 
codon Deletion
c.1219-1G>T Abberant splicing Splice site
c.1476+1G>T Abberant splicing Splice site
c.1529T>G p.Leu1529Arg Amino acid substitution Missense
c.1604del p.Leu535X
Premature termination 
codon Nonsense
c.1668+1G>A Abberant splicing Splice site
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When the results are not straight forward the non-academic medical doctor will 
eventually consult a clinical geneticist. Consequently, a clinical geneticist will 
start with a genetic profile of a patient with ARCA, followed by careful (re-)
phenotyping of the patient, and subsequently the patient will get a molecular 
diagnosis that can be linked to his/her medical disease. Eventually, molecular 
diagnostics may also provide an improved and more accurate prediction of the 
clinical course of the disease, as variants in other (modifying) genes may influence 
the severity of the disease. In addition, these novel techniques will also allow 
further research. This in turn may lead to the identification of additional genes in 
patients in whom the disease is not caused by the currently known ARCA genes.
 With this new approach world-wide databases in which genetic variations and 
mutations together with detailed clinical characteristics are collected, will be of 
crucial importance for interpreting all the data that will be generated. Eventually 
this will make personalized counseling possible. 
 The use of exome, and eventually whole genome sequencing, also raises 
some (ethical) concerns  [43].  First of all, the use of these NGS techniques may 
result in unanticipated chance findings that are not related to the original reason 
for the diagnostic test but are nonetheless medically relevant. For instance, a 
cancer disease prediction (mutations in BRCA1/2) is detected while testing for 
mutations in genes associated with ARCA.
 In the pretest counseling of patients the possibility of unforeseen outcomes 
needs to be explained but the question is whether every patient will be able to a 
priori completely understand the possible outcomes of the test. At the moment 
we are still debating how to act upon these unexpected findings, since it is 
impossible to anticipate every possible outcome or patient response in advance. 
 Next, another change in molecular diagnostics is about to evolve, RNA 
sequencing.
 So far, all studies have been focused on identifying DNA variants as disease 
susceptibility alleles, but it is very likely that RNA sequence variants in the human 
transcriptome also play a role in disease susceptibility and manifestations. The 
transmission of information from DNA to RNA is a delicate and complicated 
process. Li et al. compared the RNA sequences from human B cells to the 
corresponding DNA sequence of 27 individuals and discovered over 10,000 
exonic sites at which the RNA sequence did not match that of the DNA. These 
differences were non-random and found in multiple individuals and different cell 
types [44]. These genome variations need to be further studied, especially in 
relation to human diseases. The research section of the Department of Human 
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Genetics at the Radboud University Nijmegen Medical Centre will therefore soon 
start with RNA sequencing in patients with a clear clinical diagnosis but without a 
proven exome-associated etiology. 
Epidemiological studies
Based on experiences from our outpatient clinic for patients with neurodegenera-
tive disorders, we predict  that after FA and AT, ARSACS, AOA2 and cerebellar 
ataxia associated with POLG mutations (SANDO/MIRAS) are the most common 
ARCAs occurring in the Netherlands. However, exact data on the incidence and 
prevalence are lacking, except for AT for which an estimated incidence of 1 per 
180,000 in the Netherlands has been calculated by Verhagen et al. [45]. Not many 
epidemiological data are available for the other forms of ARCA [46-48]. The main 
reason for this is the fact that most disorders have just recently been unambiguously 
established as separate entities by the identification of their respective genetic 
causes. 
 Major regional and ethnic variations in relative frequencies of the various 
ARCAs are to be expected. The epidemiological and molecular study of a cohort 
of 102 patients with ARCA performed by Anheim et al. confirmed AT to be the 
second most prevalent (1/450,000) ARCA in Eastern France, followed by AOA2 
(1/900.000). These authors  conclude that AVED, ARSACS, AOA1, AOA2 and MSS 
probably have a prevalence close to that of AT. It would be interesting to perform 
a large European study on the frequency of the different (non-FA) ARCAs in 
Europe, together with a tabulation of the clinical characteristics of the different 
ARCAs. With the availability of NGS it will be much easier to perform such studies. 
Also, the real proportion of SYNE1 mutations in unexplained ARCA cases may 
finally be established.  ARCA1 so far has only been identified in a restricted 
French-Canadian population. However, the amount (7) of different mutations 
identified in a group of families of European ancestry renders it likely that ARCA1 
is a common cause of late-onset isolated cerebellar ataxia [49].
Importance of the Ataxia-ome
It is already known from defects in genes encoding components of the ciliary 
apparatus that single-locus allelism has been insufficient to explain the variable 
penetrance and expressivity of disorders linked to the ciliary apparatus. This 
suggests that genetic variation across multiple sites of, in this case, the ciliary 
proteome influences clinical outcome [50]. This will also be true for the ‘Ataxia - ome’. 
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Studying the Ataxia-ome is the beginning of unraveling the network of proteins 
involved in cerebellar ataxia [51]. So far this study has revealed the interaction of 
several ataxia proteins. Indeed it has turned out that there are common processes 
and pathways involved in the different cerebellar ataxias. Studies have revealed 
interactions between AFG3L2 (SCA28) involved in ADCA and paraplegin (SPG7) 
involved in spastic paraplegia associated with cerebellar ataxia, demonstrating 
further evidence of common pathways involved in cerebellar ataxias [52]. 
Furthermore, recent studies have shown that both mutated aprataxin and TDP1 
lead to mitochondrial dysfunction similar to what is known for FA, IOSCA, SANDO 
(MIRAS) and ARCA2. Altogether, there is evidence to suggest that the different 
ataxias in general, and ARCAs in particular, are linked to the same pathways or at 
least share a major part of these pathways [53, 54].
 Such a network may not only be helpful in identifying new genes involved in 
ARCA but it also generates a huge number of candidate modifier genes that may 
modulate or regulate pathogenic processes. As initial protein-protein interaction 
studies by Lim et al. failed to identify many interacting partners for the two genes 
(ATXN7 and CACNA1A) involved in autosomal dominant cerebellar ataxia [51] 
Kahle et al. designed another study to look for protein-protein interactions 
between these two genes and proteins known from the ataxia interactome. In this 
study 118 protein-protein interactions were revealed for ATXN7 and CACNA1A 
linking them to other ataxia-causing proteins and the ataxia network. Subsequently, 
they used OMIM to find out whether these genes are associated with diseases. 
Patients’ medical records were consulted to test if any of these diseases did 
co-occur with hereditary ataxia. They found that macular degeneration (MD) 
is more frequent in patients with ataxia. The ataxia network turns out to be 
enriched for proteins that interact with known MD-causing proteins, forming a 
MD-subnetwork. Two proteins of this subnetwork showed altered expression in 
the retina of Ataxin-7266Q/+ mice, indicating novel protein interactions. This may 
suggest potential pathways contributing to the pathophysiology of both macular 
degeneration and cerebellar ataxia [55]. This work nicely illustrates the importance 
of such molecular networks.  
Therapeutic possibilities
It is known that continuous coordination training by means of physiotherapy leads 
to long-term improvement of motor performance and achievements in activities of 
daily living [56]. No therapy with proven efficacy for cerebellar ataxia is available 
at the moment, neither symptomatic, nor disease course modifying.
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 Clinical trials with idebenone have been investigated in FA, but so far have not 
led to convincing results in terms of improvement of the disease [57]. Trials with 
erythropoietin and selective iron chelation are still ongoing [58, 59]. A small study 
investigated the  effects of riluzole, which has the capacity to open small 
conductance calcium activated potassium channels, which in turn reduces the 
hyperexcitability of neurons in deep cerebellar nuclei [60]. Hyperexcitability of 
these neurons is the result of reduced inhibitory input of Purkinje cells presumed 
to lead to cerebellar ataxia [61]. In patients with cerebellar ataxia of different 
aetiologies riluzole appeared to confer some symptomatic benefit, but these 
findings need confirmation[62]. 
 The current lack of effective therapeutic interventions is due to the fact that 
unraveling the exact disease-causing mechanisms involved in brain diseases has 
been complicated for the following reasons: the intrinsic complexity of the brain, 
the highly extended time course of  brain development, the protracted course of 
neurodegenerative diseases, and the difficult accessibility of  brain tissue for 
research. However, with the availability of induced pluripotent stem cells (iPSCs) 
it will be possible to study the initial development and pathology of human brain 
diseases in human neuronal tissue. IPSCs are reprogrammed cells that are 
brought back to a primitive differentiation stage (by overexpression of four genes, 
Pou5f1, Sox2, Klf4, cMyc  expressed in embryonic stem cells) similar to embryonic 
stem cells [63]. These cells are pluripotent and have the capacity to generate any 
cell in the body. Functional neurons can be induced from iPSCs obtained from 
fibroblasts by overexpression of neural transcription factors such as Asc11, Brn2 
and Mytl [64, 65]. With the possibility of reprogramming human fibroblasts into 
iPSCs and subsequently into neuronal cells[66] it will become easier to get insight 
in the disease mechanisms involved in brain diseases, such as cerebellar ataxias 
[67-70]. Furthermore iPSCs can generate large numbers of differentiated neural 
cell types in vitro to use them for repair of the nervous system and may therefore 
play an important role in the development of targeted  treatments. This would 
require effective transfer into affected brain tissue which has already been tried 
for Huntington disease using fetal neural grafts for neuronal intracerebral trans-
plantation [71]. 
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Concluding remarks
With this work, we have contributed to a further understanding of the genetic 
causes of the heterogeneous group of ARCAs and we have more clearly defined 
the phenotype of different subtypes of these disorders. 
 The identification of a novel ARCA gene  (ANO10) in ARCA3 was greatly 
facilitated by the recent availability of NGS techniques.  We are now entering a 
period in which these revolutionary molecular genetic techniques will be used not 
only in research but also for diagnostic purposes. Novel genes for ARCA will be 
identified at much higher rates. Hopefully, the majority (if not all) of the genetic 
causes for ARCA will be known within a few years. 
 Although much work still needs to be done, the identification of  the genes 
involved in ARCA will pave the way towards understanding the (complex) patho-
physiology of these disorders and eventually open up possibilities for treatment(s).
It needs to be seen whether (unbiased) exome (or even whole genome) 
sequencing or targeted resequencing of an ARCA-specific gene set will become 
the method of choice for DNA diagnostics of ARCA. The possibility of finding 
unanticipated genomic variations with medical implications is far less in the 
targeted approach, but whole exome sequencing carries the chance of finding 
novel ARCA genes.  Whatever choice, it is clear that patients with ARCA and their 
family members will greatly benefit from the possibilities of these novel techniques, 
not only in terms of diagnosis and genetic counseling, but in the next 5 to 10 years 
also in terms of treatment. 
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Summary 
The autosomal recessive cerebellar ataxias (ARCAs) constitute a heterogeneous 
group of progressive neurodegenerative disorders in which a cerebellar syndrome 
is the key clinical feature, often associated with pyramidal and extrapyramidal 
features, as well as with peripheral nerve degeneration. In the Netherlands ARCAs 
have an estimated prevalence of 5 per 100,000 individuals. In contrast to the 
rapidly increasing number of genes involved in the autosomal dominant cerebellar 
ataxias, the molecular background of recessive cerebellar ataxias has been only 
partly elucidated. Many patients with a recessive ataxia are therefore still left 
without a molecular diagnosis. Furthermore, the clinical management of such 
patients is often complicated due to clinical overlap between the different cerebellar 
ataxias, the occasional atypical phenotypes, and the genetic heterogeneity. 
The objectives of this thesis were to enhance the diagnostic process and the 
counseling of patients with ARCA, by improving our knowledge of the genetic 
background of these disorders and their accompanying phenotypic characteristics.
Chapter 1 provides an overview of the various ARCAs. In this overview the clinical 
and genetic characteristics of those ARCAs in which progressive cerebellar ataxia 
is a prominent feature and for which a molecular genetic defect is known are 
discussed, along with the emerging pathophysiological pathways. Friedreich’s 
ataxia (FA) with an estimated prevalence of 1 in 29,000 in the Western world is the 
most common and well known ARCA. The other important ARCAs, such as ataxia 
telangiectasia (AT), autosomal recessive cerebellar ataxia of Charlevoix-Sa-
guenay (ARSACS), ataxia with oculomotor apraxia type 2 (AOA2) and cerebellar 
ataxia associated with POLG mutations (SANDO/MIRAS), are as far as known 
less common.  
 The clinical and genetic heterogeneity among the ARCAs often makes the clinical 
management of these patients difficult. Table 5, which provides an overview of the 
different prominent features that can be distinguished among the ARCAs discussed 
in  this review, can be helpful in the selection of an initial genetic screen. 
 Various recessive metabolic diseases can have cerebellar ataxia as an 
associated feature. In Chapter 2 patients are described with the rare metabolic 
disease PMM2-Congenital Disorder of Glycosylation (CDG), who presented with 
mainly ataxia and cerebellar hypoplasia. Abnormal transferrin isofocusing results 
are  indicative for a congenital disorder of glycosylation. 
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However, both our patients showed normal results. Therefore, we recommend the 
measurement of phosphomannomutase activity when transferrin isofocusing is 
normal or inconclusive in patients presenting with apparently recessive inherited 
ataxia with cerebellar hypoplasia on neuroimaging and with a negative genetic 
work-up.
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an 
ARCA characterized by early-onset cerebellar ataxia with spasticity and peripheral 
neuropathy. This disorder, previously considered to be rare and only present in 
the isolated French Canadian Charlevoix-Saguenay region of Quebec, is now 
known to be a disorder with worldwide prevalence. We wondered whether 
ARSACS would also be present in the Netherlands. Therefore, we performed 
sequencing of the complete SACS gene in a selected Dutch patient group (43 
index cases)  with early-onset spastic ataxia (Chapter 3). Indeed, we could 
identify 23 (16 index) patients with mutations in SACS. Detailed neurological 
examination of these ARSACS patients showed a remarkably uniform phenotype: 
cerebellar ataxia with onset before 13 years of age, lower limb spasticity and 
sensorimotor axonal neuropathy, and cerebellar (vermis) atrophy on magnetic 
resonance imaging, consistent with the core ARSACS phenotype previously 
described. The high rate of mutations (37%) identified in this cohort of Dutch 
patients suggests that ARSACS is substantially more frequent than previously 
assumed. We believe that the availability of SACS mutation analysis as well as an 
increasing awareness of the characteristic ARSACS phenotype will lead to the 
diagnosis of additional patients, possibly even at a younger age.
The large size of the total coding sequence of SACS has precluded sequencing 
of the whole coding sequence of the gene as a routine diagnostic service. Using 
DNA analysis to confirm the clinical diagnosis of ARSACS has been hampered in 
the majority of  patients worldwide due to the lack of an efficient and cost-effective 
mutation scanning system for the SACS gene. Since automated sequencing of 
this large gene is labor- intensive, costly, and time consuming, we developed 
mutation screening of  SACS by designing a heteroduplex analysis system using 
conformation sensitive capillary electrophoresis (CSCE), which is a simple, rapid, 
reliable and sensitive technique enabling a high sample throughput and an 
automated DNA variant identification (Chapter 4). Critical issues addressed 
during the development of the CSCE system, including the position of a DNA 
variant relative to the primers and the CG-content of the amplicons, are discussed. 
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After optimization of the original design, the overall analytical sensitivity of CSCE 
for SACS was 100%, and the analytical specificity of CSCE was 99.8%. Therefore, 
we conclude that CSCE is a robust technique with a high analytical sensitivity and 
specificity, and it can readily be used for mutation scanning of the large SACS 
gene. Furthermore, this technique is less time consuming and less expensive, as 
compared to  standard automated sequencing. 
Chapter 5 describes the identification of ANO10 as a novel gene involved in a 
rather pure ARCA. By combining SNP array-based linkage analysis and targeted 
resequencing of relevant sequences in the linkage interval using next generation 
sequencing technology, we identified a mutation in a novel gene involved in ARCA. 
In a Dutch consanguineous family with three affected siblings, a homozygous 
12.5 Mb region on chromosome 3 was targeted by array-based sequence 
capture. 
 Prioritization of all detected sequence variants led to four candidate genes 
one of which contained a variant with a high base pair conservation score (phyloP 
score 5.26). This variant was a leucine-to-arginine substitution in the DUF 590 
domain of a 16K transmembrane protein, a putative calcium-activated chloride 
channel encoded by anoctamin 10 (ANO10). The analysis of ANO10 by Sanger 
sequencing in other families with cerebellar ataxia revealed three additional 
mutations: a homozygous frameshift mutation (c.1150_1151del [p.Leu384fs]) in a 
Serbian family and a compound heterozygous splice-site mutation (c.1476+1G>T) 
and a nonsense mutation (c.1604del [p.Leu535X]) in a French family. These 
findings illustrate the power of using initial homozygosity mapping with next-gen-
eration sequencing technology to identify novel genes involved in autosomal 
recessive diseases. Moreover, identifying a putative calcium-dependent chloride 
channel adds another pathway to the list of pathophysiological mechanisms that 
may cause cerebellar ataxia.
In Chapter 6, the relevance of the findings of the work described in this thesis are 
discussed and future perspectives are presented. The identification of novel 
genes involved in ARCA will not only be important for genetic counseling of the 
patient and their families, but it also provides new insight into the different 
pathways involved in ARCA. Furthermore, these findings have increased the 
possibilities for pre- and postnatal diagnosis. The clinical and genetic 
heterogeneity among the ARCAs often makes it difficult to establish a molecular 
diagnosis in a patient presenting with cerebellar ataxia.
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With the use of whole exome sequencing the diagnostic work-up of ARCAs will 
improve tremendously. With this new technique, parallel sequencing of many 
genes is within reach and will enable us to have faster and more cost-effective 
results. This will in turn lead to a better phenotypic characterization of the different 
ARCAs and to other novel genes to be identified. Better insight into the patho-
physiology of the cerebellar ataxias will ultimately give guidance to the 
development of targeted treatment(s).
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Samenvatting
De autosomaal recessieve cerebellaire ataxieën (ARCA’s) vormen een groep van 
neurodegeneratieve aandoeningen die primair gekenmerkt worden door een 
cerebellair syndroom, vaak geassocieerd met pyramidale of extrapyramidale 
verschijnselen, en perifere neuropathie. De geschatte prevalentie van ARCA’s in 
Nederland is 5 per 100.000.  Voor veel ARCA’s is de genetische oorzaak nog niet 
geïdentificeerd.  Hierdoor is voor veel patiënten met een recessieve cerebellaire 
ataxie nog geen moleculaire diagnose te stellen. Daarnaast wordt het klinisch 
beleid van deze patiënten vaak bemoeilijkt door de enorme overlap in klinische 
verschijnselen tussen de verschillende ARCA’s, de atypische  fenotypes en de 
genetische heterogeniteit.
De doelstellingen van het onderzoek beschreven in dit proefschrift waren verbetering 
van het diagnostische proces en de counseling van patiënten met ARCA door meer 
genetische oorzaken van deze ziekten op te sporen en fenotypes die geassocieerd 
zijn met deze aandoeningen beter in kaart te brengen. 
In Hoofdstuk 1 wordt een overzicht gegeven van de verschillende ARCA’s.  Alle 
klinische en genetische aspecten van de ARCA’s die een progressieve cerebellaire 
ataxie als prominent kenmerk hebben en waarvan de moleculaire oorzaak bekend 
is, worden besproken. Ook de pathofysiologie van de verschillende ziektebeelden 
wordt belicht. Ataxie van Friedreich (FA) met een prevalentie van 1 per 29.000 in 
de Westerse populatie is de meest voorkomende en bekende ARCA.
 Andere belangrijke ARCA’s, die voor zover bekend minder vaak voorkomen, 
zijn ataxia telangectasia (AT), autosomaal recessieve cerebellaire ataxie van 
Charlevoix-Saguenay (ARSACS), ataxie met oculomotore apraxie type 2 (AOA2) 
en cerebellaire ataxie geassocieerd met POLG mutaties (SANDO/MIRAS). De 
klinische en genetische heterogeniteit van de ARCA’s  bemoeilijkt het klinisch beleid 
van patiënten met deze aandoeningen. 
 Op basis van een aantal prominente klinische verschijnselen kan een eerste 
onderscheid gemaakt worden tussen de ARCA’s. In tabel 5 wordt hier een 
overzicht van gegeven. Deze tabel kan behulpzaam zijn bij de overweging van de 
selectie van genetische screening. 
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Bij verschillende  stofwisselingsziekten kan een cerebellaire ataxie voorkomen. 
In Hoofdstuk 2 worden twee patiënten beschreven met de zeldzame stofwisse-
lingsziekte PMM2-Congenital Disorder of Glycosylation (CDG), die zich presenteerden 
met voornamelijk ataxie en hypoplasie van het cerebellum. Meestal wordt de 
diagnose CDG gesteld op basis van een afwijkende transferrine isofocusing. 
Echter, beide patiënten toonde een normale transferrine isofocusing. Daarom 
raden wij aan om de activiteit van phosphomannomutase in bloed te laten 
bepalen wanneer de transferrine isofocusing normaal is bij patiënten die zich 
presenteren met een ogenschijnlijke recessieve ataxie met hypoplasie van het 
cerebellum en een eerste negatieve genetische screening. 
ARSACS is een ARCA die gekenmerkt wordt door een op jonge leeftijd beginnende 
cerebellaire ataxie met spasticiteit en perifere neuropathie. Eerder werd gedacht dat 
deze aandoening zeer zeldzaam was en alleen voorkwam in de geïsoleerde Frans 
Canadese Charlevoix-Saguenay regio in Quebec. Inmiddels is bekend dat de 
aandoening wereldwijd voorkomt. Wij vroegen ons af of deze aandoening ook in 
Nederland voorkomt. Hiertoe hebben wij het complete SACS gen gesequenced 
(uitgelezen) in een geselecteerde groep Nederlandse patiënten met een op jonge 
leeftijd ontstane spastische ataxie (Hoofdstuk 3). Met de identificatie van 16 index 
(totaal 23) patiënten met mutaties in SACS  hebben we aangetoond dat ARSACS ook 
in Nederland voorkomt. Gedetailleerd neurologisch onderzoek van deze patiënten 
toonde een opvallend uniform fenotype: cerebellaire ataxie met een beginleeftijd 
voor het 13e jaar, spasticiteit van de onderste ledematen, sensomotore axonale 
neuropathie en cerebellaire (vermis) atrofie bij beeldvorming van het brein. Dit komt 
overeen met het fenotype zoals eerder beschreven. Het hoge percentage ARSACS 
patiënten (37%) dat  we geïdentificeerd hebben in dit cohort van Nederlandse 
patiënten suggereert dat ARSACS vaker voorkomt dan voorheen gedacht werd. Wij 
denken dat met de beschikbaarheid van mutatieanalyse van SACS binnen de DNA 
diagnostiek en de toenemende kennis van dit karakteristieke fenotype er meer ARSACS 
patiënten gediagnosticeerd zullen worden, mogelijk ook op een jongere leeftijd.
Mutatieanalyse van SACS is erg arbeidsintensief en duur omdat de volledige 
coderende sequentie van het gen extreem groot is. Daarom heeft het lang 
geduurd voordat dit gen werd opgenomen binnen de routinediagnostiek van het 
DNA-laboratorium. Bevestiging van de klinische diagnose ARSACS door middel 
van DNA onderzoek vond bij veel patiënten vaak niet plaats omdat diagnostiek 
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meestal alleen in research verband mogelijk was. Daarom zijn wij op zoek gegaan 
naar een efficiënt, kosteneffectief en betrouwbaar mutatiescanning systeem voor 
SACS. Hiervoor hebben we, door gebruik te maken van een electroforesetechniek 
genaamd conformation sensitive capillairy electroforesis (CSCE), een heteroduplex 
analysesysteem ontwikkeld. Dit systeem maakt het mogelijk om mutatiescanning 
van SACS volledig automatisch en op een simpele, snelle en betrouwbare manier 
uit te voeren (Hoofdstuk 4). In hoofdstuk 4 worden de knelpunten beschreven 
waar we tegen aanliepen tijdens de ontwikkeling van het CSCE systeem, 
waaronder de positie van een DNA variant ten opzichte van de primer en de 
CG-inhoud van de amplicons. Na optimalisatie van het originele ontwerp, was de 
algehele analytische sensitiviteit van de CSCE voor SACS 100% en de analytische 
specificiteit van de CSCE 99,8%. Hieruit concluderen wij dat CSCE een robuuste 
techniek is met een hoge analytische sensitiviteit en specificiteit, en dus goed 
bruikbaar is voor mutatiescanning van het grote SACS gen. Daarnaast is deze 
techniek minder arbeidsintensief en minder duur, in vergelijking met standaard 
Sanger sequencing.
In Hoofdstuk 5 wordt de identificatie van een nieuw gen, dat betrokken is bij een 
nagenoeg pure vorm van ARCA, beschreven. Voor de identificatie van dit gen 
werd gebruik gemaakt van homozygosity mapping door middel van SNP-array 
analyse en gerichte exoomsequencing van het homozygote gebied. In een 
Nederlandse consanguine familie met drie aangedane broers en zussen werden 
alle exonen in een homozygote regio van 12,5 Mb gelegen op chromosoom 3 
gesequenced. Na het filteren en  prioriteren van alle gevonden sequentieveran-
deringen bleven er vier kandidaatgenen over, waarvan één een variant bevatte 
met de hoogste score voor evolutionaire conservering van baseparen (phyloP 
score 5,26). Deze variant betrof een leucine naar arginine verandering in het DUF 
590 domein van een 16K transmembraan eiwit, een verondersteld  calciumgeac-
tiveerd chloridekanaal dat gecodeerd wordt door anoctamin 10 (ANO10).
 Analyse van ANO10 door middel van conventionele (Sanger) sequencing in 
andere families met een cerebellaire ataxie toonde drie andere mutaties: een 
homozygote frameshiftmutatie (c.1150_1151del [p.Leu384fs]) in een familie 
afkomstig uit Servië en twee compound heterozygote mutaties, een splice-site 
mutatie (c.1476+1G>T) en een stopmutatie (c.1604del [p.Leu535X]) in een Franse 
familie. Deze bevindingen laten zien dat de combinatie van homozygosity mapping 
en next generation sequencing technologie een krachtige methode is om nieuwe 
genen op te sporen betrokken bij autosomaal recessieve cerebellaire ataxieën. 
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Daarbij heeft de ontdekking van een verondersteld calcium-afhankelijk chloride 
kanaal als betrokken bij ARCA een nieuw pathologisch substraat  toe gevoegd 
aan de reeds bekende pathofysiologische mechanismen die betrokken zijn bij 
cerebellaire ataxie.
In Hoofdstuk 6 wordt de relevantie van de bevindingen van het werk dat 
beschreven is in dit proefschrift besproken. De identificatie van nieuwe genen 
betrokken bij ARCA is niet alleen belangrijk voor de counseling van patiënten en 
hun familieleden, maar geeft uiteindelijk ook inzicht in de verschillende patho-
fysiologische mechanismen die ten grondslag liggen aan deze aandoeningen. 
Daarnaast maken deze bevindingen pre- en postnatale diagnostiek mogelijk. 
Door de klinische en genetische heterogeniteit binnen de ARCA’s is het vaak 
lastig om een moleculaire diagnose te stellen bij een patiënt met cerebellaire 
ataxie. Door gebruik te maken van exoom sequencing zal de diagnostische 
work-up van patiënten met een vermoedelijke ARCA enorm verbeteren. Met deze 
techniek kunnen we vele genen tegelijk nakijken wat er uiteindelijk toe zal leiden 
dat uitslagen snel bekend zijn en de analyses goedkoper worden. Dit zal leiden 
tot beter inzicht in de verschillende fenotypes binnen de verscheidene ARCA’s en 
tot de identificatie van meer nieuwe genen betrokken bij deze aandoeningen. 
Daarnaast zal meer inzicht in de pathofysiologie van de cerebellaire ataxieën 
uiteindelijk een leidraad vormen voor de ontwikkeling van gerichte therapie(ën).
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Dankwoord
Promoveren is als “backpacken”, van te voren weet je niet precies hoe je reis zal 
verlopen. Onderweg kom je veel verschillende mensen en omgevingen tegen. 
Het ene moment gaat je reis zoals gepland en een ander moment loopt het net 
even anders. Dit maakt het spannend en enerverend. Soms kom je op plekken 
waar je van te voren niet gedacht had te komen. En aan het einde van je reis blijk 
je meer bagage te hebben dan toen je vertrok. 
Nu ik aan het einde van deze reis ben gekomen kijk ik terug op een geweldige 
ervaring.
Zonder de medewerking van alle patiënten die betrokken zijn geweest bij dit onder- 
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Hans, in die periode dat ik het even nodig had mijn weg te vinden was jij er voor 
mij! Onze gesprekken destijds heb ik zeer op prijs gesteld. Ondanks dat ik een 
echte patiënten dokter ben, heb ik mij toch enorm thuis gevoeld bij de DNA 
diagnostiek. Dank hiervoor. Ik hoop dat we in de toekomst nog meer zullen 
samenwerken. En dat biertje houd je echt nog tegoed!
Bart, geweldig dat ook jij mijn copromotor werd. Van jou kan en hoop ik nog heel 
veel te leren! 
Ben en Han, dank voor de mogelijkheid om mij niet alleen de kans gegeven te 
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de wetenschappelijke kant.
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Graag wil ik alle collega s´ van de sectie klinische genetica hartelijk danken voor 
hun betrokkenheid en gezelligheid. 
Ilse, ik ken jou al geruime tijd als een fijne collega. Dank voor je luisterend oor, je 
goede raad en adviezen, ook toen ik het zo nodig had. 
Peggy, volgens mij zijn we inmiddels wel geslaagd voor die cursus jongleren...
Onze gesprekken doen mij altijd erg goed. Ik hoop er nog lang van te kunnen 
genieten.
Lieve “Meiden”, Barcelona here we come! Dank voor jullie heerlijke vriendschap, 
steun en begrip en voor de onvergetelijke heerlijke bijklep avonden! Moeten we 
vaker doen! Nu ECHT!
Marije, onze tijd samen begon tijdens de introductie. Wat hebben we nu terug- 
kijkend al veel samen meegemaakt. Muchas gracias por ser me amiga! 
Fantastisch dat jij op deze bijzondere dag als mijn paranimf naast mij staat.
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delijke liefde, steun en vertrouwen in mij.  Zoals jullie altijd zeggen: “ Word maar 
kapper hoar groeit altied!”. 
Allerliefste Rob, ook jij hebt soms moeten afzien. Maar, lieverd, nu komt er ECHT 
meer tijd en rust voor ons en onze twee geweldige dochters Marit en Jitte. Ook al 
vond je het soms gekkenwerk, ik waardeer het enorm dat je mij hebt gesteund 
en mij de ruimte hebt gegeven om dit uiteindelijk tot een goed einde te brengen. 
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